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ABSTRACT 
GOLD NANOPARTICLE BIODISTRIBUTIONS AND STABILITY IN VIVO FROM 
MASS SPECTROMETRIC IMAGING 
 
FEBRUARY 2017 
 
SUKRU GOKHAN ELCI  
 
B.S., IZMIR INSTITUTE OF TECHNOLOGY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard W. Vachet 
 
  
 Their smaller size, inherent non-toxicity and tunable properties of gold 
nanoparticles (AuNPs) attract researchers for their use in biological applications such as 
drug delivery, imaging and therapeutics. Understanding the in vivo fate of these AuNPs are 
essential for their potential effects in both the environment and the body. In this 
dissertation, mass spectrometric imaging methods using laser ablation inductively-coupled 
plasma mass spectrometry (LA-ICP-MS) and laser desorption/ionization (LDI-MS) have 
been investigated to monitor the in vivo fate of AuNPs. AuNP injected mouse tissue 
samples can be obtained and readily imaged to track the injected AuNPs using these 
methods. A first-ever imaging of 2 nm monolayer protected AuNPs in vivo using LA-ICP-
MS is described. In addition, sub-organ biodistribution of AuNPs using LA-ICP-MS has 
been investigated. An alternative quantification strategy that can be used for LA-ICP-MS 
is expressed. A dual mode imaging method that can be used to monitor the stability of 
AuNPs by combining LA-ICP-MS and LDI-MS is reported. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. Gold nanoparticles in history 
Gold is a precious metal that has a characteristic beautiful and bright golden yellow 
color with an Earth abundance of only 5 part per billion (ppb).1,2 In the global market, 50% 
of Au is used in jewelry, 40% in investments and 10% in other industries.3 Its relative 
scarcity makes Au one of the most precious metals in the world and is the reason why it 
was used as a currency over centuries. The malleable properties of Au allow it to be 
processed and easily formed into different shapes. It can even be hammered into very thin 
sheets or stretched into fine threads.4 In ancient times, goldsmiths knew how to hammer 
Au into very thin leafs (500 atoms thick, i.e., 144 nm). These thin leafs contributed to the 
development of modern science, providing one of the critical components (Au foil 
bombarded by α particles) for the Rutherford backscattering experiment that led to the 
establishment of the atomic nucleus model. 
Further developments allowed processing of Au into sub-100 nm structures with 
unique properties distinct from bulk Au. One of the most famous examples of nanoscale 
Au is found in the Lycurgus Cup, which displays green or red color based on how it is 
exposed to light (Figure 1.1).5 After the Lycurgus Cup, Au flakes were widely used in 
stained glass to produce church windows of various colors, noticeably the ruby red color.6 
These examples represent the early use of manmade nanomaterials. Although nanoscale 
 2 
Au was used at the time, the nature of it was not well known due to the lack of analytical 
tools to characterize such minuscule structures.  
 
Figure 1.1. Lycurgus cup under different light exposures (Reproduced from Ref 6)  
 The first known example of gold nanoparticles was reported in 1857 by Michael 
Faraday.7 In his work, he discovered “fine particles” by reacting aqueous HAuCl4 with 
phosphorous dissolved in CS2. The “fine particles” suspension showed a ruby red color, 
completely distinct from bulk Au’s golden yellow color, but at the time, there was no theory 
that could explain this observation. Other studies conducted within the last few decades 
have demonstrated an entire spectrum of varying colors of Au “fine particles.” After 
Faraday’s discovery, researchers, including Richard Zsimondy and Theodor Svedberg, 
investigated these “fine particles” and identified them as nanoscale structures made of Au.8  
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1.2. Gold nanoparticles in biological applications 
Besides the optical features of Au nanomaterials, Au has a variety of inherent 
properties that make it attractive to researchers for its use in biological applications. Gold 
is known to be the least reactive metal and can be stored for years without any oxidation.9 
This non-reactive and bioinert nature of Au makes it an excellent candidate for in vitro and 
in vivo applications. The low toxicity of Au nanomaterials has been reported in in vitro 
studies, and preliminary results indicate biocompatibility in vivo and in clinical studies.10,11 
In addition to the bio-inert nature of Au nanoparticles, Au has the well-known 
ability to form strong bonds with compounds containing thiol (-SH) or disulfide (S-S) 
groups.12 Using thiol chemistry, a wide range of self-assembled monolayers (SAM), which 
are mostly long alkanethiol or alkyl disulfides, can be attached onto the Au surface (Figure 
1.2).13 These self-assembled monolayers have been further engineered to give 
functionality, solubility in water, biocompatibility and stability to the particles.14-16 Figure 
1.3 represents the schematic structure of the monolayer attached on the Au nanoparticles 
used in this dissertation. 
 
 
 4 
Figure 1.2. Schematic illustrations of a self-assembled monolayer (SAM) of alkanethiolate 
formed on the surface of a Au substrate. (Reproduced from Ref 13) 
   
 
Figure 1.3. Schematic representation of monolayer structure 
 The unique properties and development of monolayer structures open up many 
biomedical applications such as drug delivery,17,18 imaging,19 sensors20 and therapeutics.21  
 1.3. Characterization of monolayer protected AuNPs 
The need for development of better analytical tools to characterize, detect, map and 
quantify nanomaterials has increased significantly in the 21st century. For the quality 
control purposes of the nanomaterials, their characterization is essential for defining 
physical properties such as size, shape and surface chemistry.  
Different techniques have been applied to characterize the physical properties of 
nanoparticles (NPs). For the measurement of the core size and shape, atomic force 
microscopy (AFM),22 transmission electron microscopy (TEM),23 and scanning tunneling 
microscopy (STM)24 are most commonly used. Although these techniques are capable of 
measuring core sizes of NPs, they cannot characterize SAMs attached on the surface of the 
NPs.  In addition to the above mentioned techniques, X-ray diffraction (XRD),25 and small 
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angle X-ray scattering (SAXS),26 have been utilized for characterization of NPs. Even in 
using these techniques, the characterization of SAMs on NPs remains challenging. It is 
essential to investigate new approaches for the characterization of SAMs to better 
understand the interactions of SAMs with biological molecules.27,28 
Thermogravimetric analysis (TGA)29 and nuclear magnetic resonance (NMR)30 are 
used to obtain information from SAMs. TGA provides ligand-to-core mass ratio of the 
NPs, but it cannot characterize the structure of the SAM. NMR, on the other hand, can be 
used to get structural information of the SAMs; however, peak broadening and the large 
sample size required for NMR are major drawbacks of this method. Alternatively, Fourier 
transform infrared spectroscopy (FT-IR) and UV-Vis are capable of approximate 
identification of the surface monolayers.  
 1.4. Mass spectrometric characterization of AuNPs 
Used universally as a measurement tool for the characterization of various 
compounds, mass spectrometry (MS) is a promising tool for the characterization of AuNPs. 
Laser desorption/ionization (LDI),31,32 matrix-assisted laser desorption/ionization 
(MALDI),33 electrospray ionization (ESI),34 and ion-mobility (IM) MS35 have previously 
been applied for characterization of NPs.  
The first examples of LDI-MS analysis of Au nanoparticles provided information 
for intact Au clusters but very little information was obtained for the SAMs.31 Further 
analysis was performed on AuNPs with LDI-MS and MALDI-MS.36 In those reports, 
signals from the alkanethiol monolayer and its fragments were detected. Until recently, 
these studies were limited to only certain types of AuNPs with certain number of gold 
atoms and SAMs. A wide range of core sizes have been successfully detected by MALDI-
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MS,33,37 but intact analysis of AuNPs has still been limited to NPs with certain types of 
monolayers and core sizes. 
AuNPs with intact SAMs have also been investigated by other MS techniques such 
as ESI34 and IM-MS.35 ESI-MS has been shown to provide information for intact Au cores 
with the surface monolayer attached.38 It is able to provide information on the exact 
composition of the AuNPs, but, NPs that are detectable by ESI-MS are only limited to 
certain number of core metal atoms and types of ligands attached. Ligand segregation 
information provided by IM-MS have been shown to be useful for quantifying surface 
components of NPs.39 The application of IM-MS to characterize the monolayers in 
complex matrices such as cells or tissues are undoubtedly will be challenging.  
 1.5. Detection of AuNPs 
Besides being able to characterize AuNPs for different applications, detecting them 
in a sensitive and selective way is crucial for understanding their biodistribution and 
environmental fate.40-43 Previously, AuNPs were monitored in complex systems such as 
bacteria,44 plants,45 cells46 and animal47 for understating their fate. Detection of NPs in 
complex biological systems requires analytical techniques that have a high tolerance to 
biomolecules and good selectivity. Given the complexity of biological systems, the 
techniques described above for characterization of NPs may not be suitable in order to 
analyze AuNPs in biological systems. Besides their applicability in biological systems to 
obtain quantitative information are challenging. 
Optical methods, such as confocal microscopy,48 can be used to monitor 
nanoparticles in biological systems. These techniques often require specialized optical 
equipment, though, and accurate quantitative information is typically not obtainable. 
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Alternatively, NPs can be labeled to allow their detection in biological systems.49,50 
Although this technique overcomes the challenge caused by the complexity of the 
biological system, the additional labeling may cause changes in the behavior of the NPs. 
Also, design of numerous labels for various applications are challenging. 
Elemental analysis methods like inductively-coupled plasma mass spectrometry are 
widely used for detection of AuNPs in complex biological samples.51,52 For example, using 
ICP-MS, the effect of surface properties on biodistribution of AuNPs was investigated in 
cells,53 fish54 and plants.55  Both the effect of surface charge and size on the cellular uptake 
of AuNPs have been investigated.56 In this particular work, four different AuNPs with 
different sizes and surface charges were prepared and uptake efficiencies were measured 
with ICP-MS. The quantitative Au amounts revealed the changes in the uptake of AuNPs 
with different core sizes and surface charges (Figure 1.4).  Although this method provides 
total Au amounts present in the biosystem, there is no information obtained from the SAMs 
present on the AuNPs. 
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Figure 1.4. a) Structure of the AuNPs investigated in this study with cationic, zwitterionic 
and anionic headgroups b) Cellular uptake of AuNPs with different core size by HeLa cells 
after 3 h incubation in serum-free media. ICP-MS used for determination of gold per cell 
amounts and values are indicated in the histogram. c) Uptake trend of AuNPs with different 
sizes. Efficiency of the uptake of 4 and 6 nm NP was normalized to that of 2 nm NP with 
the same surface charge. Mean values ± standard deviation, n = 3. (Reproduced from Ref 
56) 
 Several other mass spectrometric methods, such as LDI, MALDI, ESI and IM have 
been investigated for the detection of monolayers in pure samples. Although successful 
detection of monolayers have been shown with these methods, applicability of them in 
biological matrices are challenging. During analysis of the AuNPs in biosystems with 
MALDI-MS and ESI-MS, ionization of biomolecules can cause interferences that could 
prevent detection of the monolayers.57,58  LDI-MS is the most promising method in terms 
of obtaining interference-free information from the intact monolayers on the AuNPs.59 It 
can also provide multiplexed detection of monolayer simultaneously in complex 
biosystems.59,32  
In LDI-MS, a laser irradiates the sample and the energy provided from the laser is 
absorbed by the NP core.60,61 This absorbed energy is then transferred to the monolayer on 
the NP surface, which then desorbs/ionizes. Using this method, characterization of a wide 
range of NPs with various NP core materials can be achieved since most core materials 
bound to the monolayer on the NPs surface can efficiently absorb at wavelengths such as 
337 and 355 nm, which are the laser wavelengths commonly used in commercial mass 
spectrometers. For example, alkanethiol compounds attached to the AuNPs surface can be 
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detected using this method because the Au core can readily absorb the laser energy and 
transfer it to cleave the Au-S bond to desorb/ionize the monolayer.62 This localized energy 
transfer between the NP core and the monolayer allows us to obtain interference-free 
signals from the monolayer attached to the NP core and very high selectivity. These 
advantages of LDI-MS enable its use in biological applications. Previously, our group 
demonstrated the detection of AuNPs in biological samples such as cells32 and tissues59.  
In addition, other researchers have also utilized this selective ionization process for various 
applications including use of AuNPs as MALDI matrices.63,64 
1.6. Imaging of AuNPs using mass spectrometry 
Monolayer protected AuNPs are widely investigated in biological applications 
because they provide desired functionalities, protection and biocompatibility for these 
applications.65,66 The environmental exposure of these AuNPs and their biodistribution is 
a growing concern. For this reason, there is an urge for development of new methods that 
could track AuNPs in complex biosystems.67 Different approaches, such as magnetic 
resonance imaging (MRI),68 Raman spectroscopy,69,70 surface plasmon resonance 
(SPR),71,72 and fluorescence microscopy73,74 have been used to obtain site-specific 
information of nanomaterials. However, each of these techniques require specific 
properties to allow the detection of the NPs. Another method known as the radionuclide-
labeling also has similar limitations as described.75 Although these techniques are capable 
of providing useful information about NPs distribution in biological systems, it is very 
challenging to obtain site-specific quantitative measurements. In addition, simultaneous 
monitoring of multiple NPs is not easy with these methods. To overcome the described 
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challenges of monitoring NPs with quantitative information, alternative tools are 
necessary.  
A most common method for obtaining biodistribution information for AuNPs is 
ICP-MS. Quantitative information from the core material of any metal NP can be obtained 
with high sensitivity using ICP-MS. Since every species transforms into an atomic form in 
the plasma, any metallic NP in any biological matrix can be monitored after sample 
digestion. While, the total amounts of the NPs can be detected in any matrices, any site-
specific information is lost due to sample digestion. In addition, the sample preparation is 
time-consuming and it is unclear whether the NPs are still intact in vivo or not. 
In the last decade mass spectrometric imaging techniques allowed researches to 
monitor biomolecules such as proteins,76,77 peptides,78 lipids,79 and other biomolecules80,81 
in tissue samples. Besides biomolecules, hyphenated sample introduction systems [i.e. 
laser ablation (LA)] with ICP-MS allowed monitoring the biodistribution of metals present 
in tissue samples.82,83 The applicability of LA-ICP-MS for NPs has been also demonstrated 
in biosystems such as cells,53,84 tissues85,86 and plants.87 Although LA-ICP-MS can 
successfully monitor the NPs in vivo, it still cannot identify if the NPs are still intact in the 
tissues. It is also challenging to obtain multiplexed information for the NPs with same core 
material. On the other hand, LDI-MS can provide the desired information for the 
monolayer of the NPs, even in complex biosystems such as cells32 and tissues.59 This 
technique can also monitor the NPs in a multiplexed fashion to obtain site-specific 
information of the biodistribution of the NPs. Quantitative imaging of these nanomaterials 
are possible with the appropriate standards.  
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While LA-ICP-MS has been used to detect NPs in biological systems, it has not 
been used to measure very small NPs that are commonly used in biomedical applications. 
Much of the work described in this dissertation will demonstrate the first examples of 
quantitative imaging of 2 nm monolayer protected AuNPs using LA-ICP-MS in mouse 
tissues. Previously, LA-ICP-MS have been used to monitor biodistribution of NPs in vivo 
with sizes up to 13 nm.82 Most of the previous works revealed the overall biodistributions 
of the NPs in tissue. To better understand in vivo fate of the NPs, the research described 
here will show sub-organ biodistribution information for AuNPs in tissues.  Furthermore, 
using a combination of both elemental and molecular mass spectrometric imaging methods, 
it will be shown if the NPs are still intact or not in mouse tissues. 
1.7. Dissertation overview 
LA-ICP-MS has been shown to monitor AuNPs in complex biological systems such 
as cells53,80 and tissues.81,82  This method is based on ablation of solid materials with a laser 
and transfer of the ablated material via a carrier gas into the plasma of the ICP-MS. Highly 
sensitive detection of NPs are achieved with this method and quantitative information for 
the biodistribution of NPs is obtained with appropriate standards.88,89 Information 
regarding whether or not the AuNPs are intact in vivo is provided with LDI-MS imaging.59 
Similar to LA-ICP-MS, this method is based on selective desorption/ionization of the 
monolayer on the NPs surface with laser irradiation. Use of mass barcodes instead of any 
other labeling strategies allows monitoring the biological fate of NPs on their uptake and 
monolayer stability.90 For effective use of NPs, their biodistribution needs to be monitored 
in order to modulate their potential environmental, health and safety effects. Currently, 
there are limited analytical tools for tracking, quantifying, and imaging NPs in biological 
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and environmental systems. In this dissertation quantitative biodistribution of AuNPs and 
their stability in mouse tissues will be revealed by mass spectrometric imaging techniques. 
In Chapter 2, the first-ever imaging of 2 nm monolayer protected AuNPs in vivo 
using LA-ICP-MS will be described. How LA-ICP-MS imaging can be used to quantify 
and monitor 2 nm monolayer protected AuNPs in vivo will be demonstrated. Three 
different AuNPs with varying surface charges (positive, negative, neutral) have been 
investigated. The findings show that to obtain accurate quantitative information for AuNPs 
in vivo, it is critical to choose a matrix that is well matched with the tissue of interest. In 
addition, initial observation showed that the surface charge affected the biodistribution of 
the AuNPs.  
In Chapter 3, an alternative quantification method that could be used for LA-ICP-
MS imaging will be described. Matrix-matched quantification methods require time-
consuming sample preparation and the matrix choice is critical for accurate quantification. 
Inkjet printing is explored as an alternative and is used to obtain standard samples that 
could be used for quantification of AuNPs in vivo. It will be demonstrated how inkjet 
printing can be used to print that standard samples and how that can be used for 
quantification of AuNPs in tissue samples.  
The initial differences observed on the biodistribution of AuNPs will be further 
investigated using LA-ICP-MS in Chapter 4. Four different AuNPs with varying surface 
charge were investigated. In three different mouse tissues, our observations show that the 
surface charge dictates the biodistribution of the AuNPs. In addition, using the 
Hematoxylin and Eosin Y (H&E) staining, sub-organ regions of the tissue were identified 
and quantitative information about the biodistribution of AuNPs were determined.  
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Finally, to better understand the in vivo fate of the AuNPs, a dual-mode imaging 
method that can monitor the stability of AuNPs in a site specific manner will be 
investigated. Three different parameters that can affect the stability of the particles (time, 
organ, NP surface chemistry) were investigated. Time dependent results indicate that the 
stability of the particles are lost over time. It was also discovered that organ bio-
composition dramatically affects the stability of the particle. The NP surface chemistry 
design is also important to obtain stability within same tissue environment.  
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CHAPTER 2 
 
QUANTITATIVE IMAGING OF 2 nm MONOLAYER PROTECTED GOLD 
NANOPARTICLE DISTRIBUTION USING LASER ABLATION 
INDUCTIVELY-COUPLED PLASMA MASS SPECTROMETRY (LA-ICP-MS)  
 
This chapter is adapted from a paper published as: Elci, S. G.; Yan, B.; Kim, S. T.; Saha, 
K.; Jiang, Y.; Klemmer, G. A.; Moyano, D. F.; Yesilbag Tonga, G.; Rotello V. M.; Vachet, 
R. W. Analyst 2016, 141, 2418-2425. 
2.1 Introduction 
Nanomaterials are widely used in biomedical applications such as drug delivery, 
therapeutics, sensors and other nanodevices.1-3 Functionalized nanoparticles (NPs) have 
tailorable sizes and surface properties that allow them to be tuned for a wide range of 
biomedical applications. For example, NP surface chemistry can be designed to influence 
their absorption, distribution, metabolism, excretion, and toxicity.4,5  Gold NPs (AuNPs), 
in particular, have been widely studied because they possess unique qualities that make 
them appealing for biomedical applications. Especially, gold’s inherent non-toxicity is the 
main property for its selection on biological applications. Besides, AuNPs can be readily 
synthesized to have a range of sizes, and their surface properties can be easily modified by 
taking advantage of gold-thiol chemistry.6,7 In recent years, there has been a rapid increase 
in the use of AuNPs in drug delivery,8 sensing,3 cancer diagnosis and therapy,9 and even 
environmental studies.10,11  
 22 
Several approaches have been applied to understand the fate of the AuNPs in vivo. 
A commonly used approach is surface-enhanced Raman spectroscopy (SERS), which 
relies on the plasmonic properties of AuNPs and how these properties change during 
interactions with each other and with biological systems.12-15 The use of SERS for 
quantitation, however, has been very limited.  Electron microscopy is commonly used to 
image NPs in biological samples. This technique is typically low throughput, though, and 
does not broadly lend itself to reliable quantitative information, despite some recent 
nanopipette-based approaches to address this issue.16 X-ray spectroscopies have also been 
used to image AuNPs17,18 and other NPs,19,20 but these techniques require difficult to access 
instrumentation such as synchrotron sources.  
Laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) is an 
emerging method for imaging NP distributions in biological systems21-23 This technique 
has high sensitivity, multi-element detection capability, and spatial resolutions in the 25-
50 µm range that make it suitable for tissue analyses. In addition, quantitative images can 
be obtained when using the appropriate standardization approaches.24-26 To date, several 
reports have described the imaging of nanomaterials in cells,27-29 tissues30-32 and plants.33 
A few of these studies have involved AuNPs, yet all but one33 have measured AuNPs with 
core sizes between 13 and 50 nm. AuNPs with smaller core sizes (< 5 nm) are biomedically 
interesting because these systems have high payload to carrier ratios. Also, together with 
their monolayer coatings these NPs are just large enough to avoid being cleared by the 
kidney but small enough to have sufficient circulation times for therapeutic applications.34 
The challenge of detecting and imaging these smaller AuNPs, however, is the fact that they 
 23 
contain much less gold than their larger counterparts. For example, a AuNP with a 2 nm 
core diameter has 1000 times less gold than a AuNP with a 20 nm core.  
In this chapter, quantitative imaging of functionalized AuNPs with 2 nm cores will 
be demonstrated. It is demonstrated that LA-ICP-MS imaging provides sub-tissue 
biodistribution information that is valuable for understanding the biological fate of AuNPs 
in vivo. Moreover, we find that the AuNPs remain intact in vivo as different surface 
monolayers cause distinct sub-tissue distributions. Overall, these measurements open the 
door for studying how surface chemistry influences AuNP biodistributions, with important 
implications for the design of NP-based therapeutics.  
2.2 Results and Discussion 
Three different AuNPs (Figure 2.1, AuNPs 1-3) were selected to investigate the 
ability of LA-ICP-MS to image AuNPs in mouse tissues. The AuNPs consist of a 2 nm Au 
core (Figure 2.10) and monolayers attached to the core via a thiol group (Figure 2.1). The 
design of the monolayer structure provides biocompatibility, solubility in water and 
stability for these AuNPs.8 Indeed, previous studies have shown that this NP design is 
biocompatible in fish and mice35-37 and that this design allows the NPs to remain intact in 
vivo.37 Spleen, liver, lung, and kidney tissues were selected for imaging because separate 
ICP-MS experiments on tissue homogenates indicated that these tissues were the main sites 
of Au accumulation after NP injection (Table 2.1). Moreover, these organs represent a 
range of tissue types with various sub-tissue features. 
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Figure 2.1. Structures of AuNPs used in this study. 
 
Table 2.1. Summary of ICP-MS quantification of homogenized tissue samples from mice 
injected with AuNPs. 
 ICP-MS (ng/g)
a
 
Mouse 
Tissue 
AuNP 1 AuNP 2 AuNP 
3
b 
Control 
Spleen 6000 ± 
400 
600 ± 
100 
1200 ± 
300 
8 ± 1 
Liver 3400 ± 
400 
1000 ± 
200 
2600 ± 
500 
2 ± 1 
Lung 700 ± 
100 
110 ± 
40 
40 ± 5 3 ± 2 
Kidney 60 ± 30 55 ± 10 60 ± 5 2 ± 1 
a The standard deviations (n = 3) are obtained by averaging the ICP-MS results obtained 
from three different mice injected with the indicated NP. 
b The standard deviations (n = 2) are obtained by averaging the ICP-MS results obtained 
from two different mice injected with the indicated NP (Three mouse used for injection 
initially but the injection on one of the mouse was not successful, to avoid more mouse 
sacrifice, two of the successfully injected mouse were used). 
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To arrive at the optimal parameters for quantitative laser ablation analysis of the 
AuNPs, we deposited AuNPs on glass slide using an inkjet printer in a manner similar to 
that described previously.38 Laser energy, frequency, scan rate, and spot size were 
investigated, and laser energy and scan rate were found to be particularly important for 
obtaining homogeneous Au signals for images with optimal resolution (Figure 2.2). We 
found that the best images were obtained with a laser energy of 3.34 J (40% power) and a 
scan rate of 10 µm/sec, which is slower than most LA-ICP-MS imaging applications that 
typically use a scan rate above 30 µm/sec. 
 
 
Figure 2.2. Identification of laser ablation condition for optimal resolution. a) 
Optimization of the laser scan rate showing the homogeneous ablation at 10 µm/s. b) 
Optimization of the laser energy showing homogeneous signal at a laser energy percentage 
of 40%, which corresponds to 3.34 J. Optimal values were identified by finding conditions 
that lead to relatively constant signals over a 500 μm space of inkjet-printed AuNPs. 
Upon identifying optimal imaging conditions, we first examined spleen tissues 
because its distinct histological regions (i.e. red pulp and white pulp) particularly reveal 
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the value of LA-ICP-MS imaging (Figure 2.3 and Figure 2.4). From Figure 2.3, it is clear 
that Au accumulates in the red pulp region (i.e. red/orange color in optical image of Figure 
2.3a) but not in the white pulp region (i.e. white circles in optical image of Figure 2.3a and 
pale red regions in the 57Fe images in Figure 2.3c) of the tissue after injection of AuNP 1. 
The role of the red pulp is to remove antigens, microorganisms and dead erythrocytes from 
the blood, while the white pulp contains different lymphocytes that are important in 
immune responses. These images suggest that AuNP 1 is filtered from circulation but is 
not taken up by the lymphocytes that comprise the white pulp. 
 
Figure 2.3. a) Optical image of a spleen tissue taken from a mouse injected with AuNP 1. 
The red pulp is red/orange in color, whereas the white pulp is white and can be challenging 
to distinguish from the area surrounding the organ in this image. Selected red pulp regions 
are indicated with red arrows, whereas selected white pulp regions are indicated with black 
arrows. b) LA-ICP-MS image of the same spleen showing the distribution of gold. c) LA-
ICP-MS image of the same spleen showing the distribution of the iron. (cps=counts per 
second) 
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Figure 2.4. H&E staining images of the spleen tissue (black arrows illustrating the white 
pulp regions and the rectangle zoom in region gives a closer look to the white pulp region 
in the yellow dashed line). 
LA-ICP-MS images of spleens taken from mice injected with AuNPs 2 and 3 are 
also readily obtained (Figure 2.5), even though these AuNPs accumulate in the spleen to a 
much lesser extent than AuNP 1 (Table 2.1). The images in Figure 2.5 illustrate that the 
red pulp is the primary site of accumulation for both NPs; however, AuNP 2 clearly 
distributes to some extent in the white pulp as well. This observation is in stark contrast to 
the behavior of AuNPs 1 and 3, indicating that NP surface chemistry influences how the 
NPs distribute internally. Importantly, because the different AuNPs show different 
distributions, the NPs very likely remain intact in vivo, highlighting the fact that our 
measurements are reporting on the AuNP distributions and not just total gold. Previously, 
we have investigated the particles with tetra ethylene glycol (TEG) and without TEG group 
on C11 chain particles. The particle with TEG showed high stability in cell and imaging 
them in spleen tissue with LDI-MS showed that the particles were still intact.39,47  
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Figure 2.5. a) Optical image of a spleen tissue taken from a mouse injected with AuNP 2. 
b) False color optical image of a spleen tissue taken from a mouse injected with AuNP 2. 
c) LA-ICP-MS image of the same spleen tissue showing the distribution of gold. The light 
gray regions indicate the white pulp. d) Optical image of a spleen tissue taken from a mouse 
injected with AuNP 3. e) False color optical image of a spleen tissue taken from a mouse 
injected with AuNP 3. The light gray regions indicate the white pulp. f) LA-ICP-MS image 
of the same spleen tissue showing the distribution of gold. (cps=counts per second) 
We were also able to obtain valuable images from liver, kidney, and lung tissues 
(Figure 2.6). The liver, which typically accumulates the second highest level of AuNPs in 
our experiments (Table 2.1), is responsible for removing toxic substances from circulation 
by storing or detoxifying them. In general, the liver shows a more homogeneous 
distribution of AuNPs than the spleen; however, we do find that AuNP 1 accumulates more 
in liver tissue surrounding the blood vessels rather than in the blood vessels themselves 
(Figure 2.6b). This observation can be confirmed by comparing the images of the Au 
distributions with the images of 57Fe distributions (Figure 2.6c). Fe is more homogeneously 
distributed throughout the liver tissue, including in the blood vessels. Significant levels of 
Au are not found in the blood vessels, suggesting rapid uptake of AuNP 1 into the 
surrounding tissue and clearance from circulation. Interestingly, AuNPs 2 and 3 show a 
broader distribution throughout the liver, including in the blood vessels (Figure 2.7). The 
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fact that AuNPs with different surface chemistries distribute differently highlights the fact 
these images are revealing AuNP distributions and not just bulk gold distributions. 
Somewhat surprisingly we also find AuNPs in lung tissue, even though the NPs 
were injected intravenously (Figure 2.6d and e). Gold measurement in this tissue is likely 
due to the large amount of blood circulating through the lungs to remove gaseous 
molecules. Presumably, the AuNPs are taken up by the tissue surrounding the alveolar 
spaces, which are seen as black in the optical image of Figure 2.6d. Lastly, we have also 
obtained images of kidney tissues (Figure 2.6f and g), which is remarkable in that these 
tissues typically accumulated less than 100 ppb of Au as determined from the tissue 
homogenate samples (Table 2.1). While the Au levels were low in the kidney, it is clear 
that Au is distributed throughout the kidney with certain regions having higher 
concentrations. In addition, removal of particle that are greater than 5 nm size is not 
possible from kidney40 and as a result of that the particles might be accumulating in the 
spleen and liver at a higher extent. The full implications of these distributions are not clear.  
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Figure 2.6. a) Optical image of a liver tissue taken from a mouse injected with AuNP 1. 
The red spots in the optical image represent the blood vessels that traverse through the liver 
(black arrows indicate the portal veins present. b) LA-ICP-MS image of the same liver 
showing the distribution of gold. c) LA-ICP-MS image of the liver showing the distribution 
of Fe. d) Optical image of a lung tissue taken from a mouse injected with AuNP 1. e) LA-
ICP-MS image of the same lung tissue showing the distribution of gold. f) Optical image 
of a kidney tissue taken from a mouse injected with AuNP 1. g) LA-ICP-MS image of the 
same kidney tissue showing the distribution of gold. (cps=counts per second) 
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Figure 2.7. a) Optical image of a liver tissue taken from a mouse injected with AuNP 2. b) 
LA-ICP-MS image of the same liver tissue showing the distribution of gold. c) Optical 
image of a liver tissue taken from a mouse injected with AuNP 3. d) LA-ICP-MS image of 
the same liver tissue showing the distribution of gold. (cps=counts per second) 
Having established that LA-ICP-MS can indicate the distributions of functionalized 
2 nm AuNPs in mouse tissues, we next investigated the possibility of generating 
quantitative images. To achieve this quantitation, we investigated a matrix-matching 
approach in which we spiked known concentrations of AuNPs into sets of tissue 
homogenates (Scheme 2.1). Ideally, appropriate mouse tissues would be used as the matrix 
for the organs of interest, but the small size of mouse organs and the unnecessary sacrifice 
of mice caused us to study more readily available tissues. We investigated chicken breast 
and beef liver as tissue phantoms for matrix matching and found that chicken breast worked 
well as a matrix match for the spleen, kidney and lung, whereas beef liver was more 
appropriate for liver tissues. 
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Figure 2.8. a) Example calibration curve obtained for AuNP 3 using chicken breast 
homogenate as the matrix. b) Quantitative LA-ICP-MS image of a spleen taken from a 
mouse injected with AuNP 3 with the zoomed in region of the white pulp. c) Quantitative 
LA-ICP-MS image of a spleen taken from a mouse injected with AuNP 2 with the zoomed 
in region of the white pulp. 
Using the matrix-matching strategy we were able to quantify AuNP distributions in 
tissues. Figure 2.8 shows the data for spleen tissue from a mouse that was injected with 
AuNP 3. Using chicken breast homogenate, we obtained the calibration curve for the spleen 
tissue using five different NP concentrations (Figure 2.8a). The calibration curve was 
obtained by averaging the Au signal from the entire tissue homogenate slice, and then this 
curve was used to obtain quantitative images for the spleen (Figure 2.8b). As was seen in 
Figure 2.8b, AuNP 3 is distributed solely in the red pulp, but now AuNP amounts at specific 
locations are apparent. Site-specific quantitation is particularly valuable for spleen images 
of AuNP 2 (Figure 2.8c), which show significant levels of Au in the white pulp regions. 
The quantitative images indicate that 50 ± 25 ppb (or about 10%) of the NPs is found in 
the white pulp regions, whereas 300 ± 80 ppb (or about 60%) is found in the red pulp and 
a remarkable 150 ± 50 (or about 30%) is found in the one pixel-wide regions that surrounds 
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each white pulp region. This latter narrow (~ 40 μm) region around the white pulp is known 
as the marginal zone and is the location where the spleen’s immune response is initiated.41 
The full implications of these results are beyond the scope of this work and will be 
investigated in future work. 
To help validate these data, we compared the average quantity obtained across this 
entire spleen slice to a part of the same spleen tissue that had been homogenized and 
analyzed by ICP-MS. In doing so, we find that the average Au amount in the tissue slice is 
within a factor of 2 of the tissue homogenates (Table 2.2). This level of agreement is 
excellent, given that the tissue slice represents only a very small fraction of this 
heterogeneous tissue, whereas the ICP-MS results were obtained from approximately one 
half of the entire spleen tissue.   
Quantitative images were also obtained for several other tissues and NPs. For the 
spleen, lung, and kidney we find good agreement between the LA-ICP-MS data and the 
ICP-MS results from the tissue homogenates when chicken breast is used as the calibration 
matrix (Table 2.2). For liver tissues, chicken breast was not found to be a reliable matrix 
for quantification, as the LA-ICP-MS and ICP-MS results usually did not compare well 
(Tables 2.1 and 2.2). Instead, beef liver homogenates were found to be a more reliable 
matrix, allowing for a more reasonable comparison between the LA-ICP-MS and ICP-MS 
results (Tables 2.1 and 2.2). Upon applying the appropriate calibration curves for each 
tissue, we are able to estimate detection limits for this LA-ICP-MS imaging method. Gold 
amounts around 10 ng/g (i.e. 10 ppb) or higher in tissue sections provide useful quantitative 
information, as is evident in the images of kidney tissue (Figure 2.9 and Table 2.1). This 
 34 
concentration is similar to the detection range seen in previous LA-ICP-MS of transition 
metals, which were found to be detectable in the 10 – 300 ng/g (i.e. 10 – 300 ppb) range.21  
 
Figure 2.9. Quantitative LA-ICP-MS images of a lung (a) and a kidney (b) taken from a 
mouse injected with AuNP1. 
 
Table 2.2. Summary of LA-ICP-MS quantification results of tissues slices from mice 
injected with AuNPs. 
Mouse Tissue LA-ICP-MS 
(ng/g)
a
 
Spleen (AuNP1) 9000±2000* 
Spleen (AuNP2) 500±150** 
Spleen (AuNP3) 6000±4000** 
Liver (AuNP1-liver homogenate) 10000 
Liver (AuNP2-chicken breast 
homogenate) 
11000 
Liver (AuNP2-liver homogenate) 450 
Liver (AuNP3-liver homogenate) 3700 
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Lung (AuNP1) 300 
Kidney (AuNP1) 80 
a The LA-ICP-MS quantitative data obtained by summing the data obtained for each pixel. 
*n=2, **n=3 
2.3. Conclusion 
In this work, we demonstrate that LA-ICP-MS can be used to quantitatively image 
the biodistributions of monolayer-protected AuNPs with 2 nm cores. To our knowledge, 
this is the first report on quantification of < 10 nm core AuNPs in animal tissues using LA-
ICP-MS. We achieve excellent sensitivity and spatial resolution in these imaging 
experiments, allowing us to determine how AuNPs with different monolayer coatings 
distribute in vivo. Thus, our approach provides useful insight into not only how NPs 
distribute but also how they are processed in vivo. This latter information is accessible from 
the sub-organ NP distributions in tissues such as the spleen and liver. We also find that the 
proper choice of matrix for the calibration standards is essential for obtaining quantitative 
images. Taken together, this imaging approach will provide important tissue/organ 
distribution data that will greatly facilitate the design and study of nanomaterials for 
biomedical applications.  
2.4. Experimental 
2.4.1. Synthesis of 2 nm AuNPs 
The AuNPs used in this study (Figure 2.1) were synthesized by the Brust-Schiffrin 
two-phase method, and were post-functionalized using the Murray place exchange 
reaction.42,43 The details of the synthetic procedure for the NPs used in this study are 
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reported in previous work.44-46 After synthesis, the AuNPs were dialyzed for 72 h against 
MilliQ water using Spectra/Por Dialysis Membranes (molecular weight cutoff of 1,000 Da) 
to separate the free ligands from the AuNPs. The core sizes of the NPs were then measured 
by transmission electron microscopy (TEM) on a JEOL100S electron microscope and were 
found to have core diameters that are 2.0 ± 0.1 nm, 1.8 ± 0.2 nm and 2.0 ± 0.4 nm for AuNP 
1, 2, and 3, respectively (Figure 2.10). They were also characterized by laser-
desorption/ionization mass spectrometry to confirm the monolayer coating.47 
 
Figure 2.10. a) TEM image and b) core size distribution of AuNP 1, c) TEM image and d) 
core size distribution of AuNP 2, e) TEM image and f) core size distribution of AuNP 3. 
2.4.2. Animal Experiments 
Animal care: All animal experiments were conducted in accordance with the 
guidelines of Institutional Animal Care and Use Committee (IACUC) at University of 
Massachusetts Amherst. Female Balb/c mice were purchased from Jackson Laboratory 
(Bar Harbor, ME). Food and water intake were assessed daily. 
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Intravenous injection of AuNPs: 50 μL of each AuNP at a concentration of 2 μM 
was administered intravenously to the Balb/c mice. Because the average NP core sizes are 
about 2 nm, the total gold amount of injected in case was approximately 4000 ng, which is 
expected given that around 200 gold atoms are present in each AuNP.48 After 24 h, the 
mice were sacrificed by the inhalation of carbon dioxide and cervical dislocation. The 
organ samples were then harvested for analysis. Following sacrifice, organs were collected 
and cut into two parts, except the kidneys and lungs of which each mouse has two. One 
part or one of the duplicate organs (in the case of the lung and kidney) was homogenized 
and analyzed by ICP-MS for total gold, while the other was used for LA-ICP-MS imaging.   
 
Tissue preparation for imaging: Using a LEICA CM1850 cryostat, tissue samples 
were sliced to a thickness of 12 μm (for spleen and liver) or 20 μm (for kidney and lung) 
at -20 °C. Then, the sliced tissues were attached to regular glass slides.  
2.4.3. ICP-MS sample preparation and measurements 
Using a 3:1 (v:v) mixture of HNO3 (68%) and H2O2 (30%), each organ was digested 
overnight. The next day 0.5 mL of aqua regia was added, and the sample was then diluted 
to 10 mL using de-ionized water. (Aqua regia is highly corrosive and must be handled 
with extreme caution.) Au standard solutions (gold concentrations: 20, 10, 5, 2, 1, 0.5, 0.2 
and 0 ppb) were prepared prior to each experiment. A Perkin Elmer NEXION 300X ICP 
mass spectrometer was used for the analysis of samples. Prior to the analysis, daily 
performance measurements were done to ensure the instrument was operating under 
optimum conditions. Using the standard mode, 197Au signals were obtained. The RF power 
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for the ICP was 1.6 kW, and the nebulizer gas flow rate was within a range of 0.9-1 L/min. 
The plasma gas flow rate and auxiliary gas flow rate were 16.5 L/min and 1.4 L/min, 
respectively. The analog stage voltage and pulse stage for the detector were -1600 V and 
950 V, respectively. The deflector voltage was set to -12 V, and 50 ms was selected for the 
dwell time during the operation of the ICP-MS.   
2.4.4. LA-ICP-MS measurement conditions and imaging 
For imaging of the tissue samples, a CETAC LSX-213 G2 laser ablation system 
(Photon Machines, Omaha, NE, USA) attached via a 2 m length of tubing to the ICP mass 
spectrometer was used. Optimization of the laser ablation conditions was first performed 
using pure AuNP samples on glass slides. As described in the results and discussion, the 
optimal conditions were found to be: a laser energy of 3.34 J, a spot size of 50 µm, a scan 
rate of 10 µm/sec, and laser shot frequency of 10 Hz. The energy value obtained directly 
from the instrument’s indicator of the laser parameter where it shows the laser energy. 
Laser scanning was done in the line scan mode. Transfer of the ablated material from the 
ablation chamber to the plasma was accomplished using a 600 mL/min flow of He gas and 
a 10 sec shutter delay. The mass spectrometer was operated using the kinetic energy 
discrimination mode, which was especially important for measurements of 57Fe. 
2.4.5. Data analysis and image generation 
ICP-MS data were analyzed using Excel and Origin 9.0 (from OriginLab, 
Northampton, MA, USA). Using Excel, each of the line data collected were processed to 
obtain the pixel size of 50 µm x 50 µm. This is achieved by summing up 5 seconds of the 
data collected (10 µm/s scan rate x 5 second leads to 50 µm length) and used as the single 
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individual pixels.49 Images of the LA-ICP-MS data were generated using the software 
ImageJ. Optical images of the tissues were processed with Adobe Photoshop. 
 
2.4.6. Matrix-matched standard preparation for LA-ICP-MS 
Homogenate preparation: Chicken breast and beef liver were purchased from a 
local market and used as the matrix-matched standards. Small pieces of these tissues were 
cut and placed in 15 mL plastic tubes. Water was added to the tubes, and the tissues were 
homogenized using a PowerGen 125 homogenizer (Fisher Scientific). Homogenized 
tissues were transferred into 1.5 mL centrifuge tubes and were centrifuged at 12000 rpm 
for 10 minutes. Using a pipette, excess water in the supernatant was removed from each 
centrifuge tubes, and 50 mg homogenates were weighed and transferred into 0.5 mL tubes. 
50 μL of 2 µM AuNP solutions were then mixed with the 50 mg homogenates. The AuNP-
homogenates mixtures were then placed into a homemade sample holder and frozen prior 
to slicing at the desired thickness on the cryostat.  
Sample holder preparation: To prepare the sample holder for matrix matched 
standards, a 50 mL centrifuge tube was cut at the 35 mL line and the top part of the tube 
with the cap was used. The tube was then filled with optical cutting temperature (OCT) 
solution. Five Edvotek 0.5-10 µL ultra pipet tips were attached to a piece of tape and slowly 
placed into the OCT solution. The resulting set up was placed in a freezer until the OCT 
solution was completely frozen. The embedded tips were then removed with tweezers, and 
the gold nanoparticle-tissue homogenate mixture was deposited into the five spaces that 
remained in the frozen OCT. 
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Scheme 2.1. Illustration of matrix-matched standard preparation. 
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CHAPTER 3 
 
QUANTITATIVE IMAGING OF GOLD NANOPARTICLES IN TISSUES USING 
INKJET-PRINTED STANDARDS 
3.1. Introduction 
 Several approaches have been applied to understand the fate of the AuNPs in vivo, 
including laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) 
imaging.1-4 Although most of these techniques are capable of generating biodistribution 
maps for the AuNPs in vivo, they lack of quantitative abilities. In this sense, LA-ICP-MS 
imaging is a promising tool with available quantification methods.5,6 
 The most commonly used quantification strategy for LA-ICP-MS imaging is to use 
matrix-matched calibration standards.7 In this approach, calibration standards are prepared 
from materials that are as similar to the sample that is analyzed.8 Although, this procedure 
is widely applied in LA-ICP-MS imaging, the laborious sample preparation, heterogeneous 
distribution of standards, and the difficulty of matching with the original sample’s 
composition are the major drawbacks of the method. Several other approaches, such as 
spin coating,9 internal and external calibration,6,10 and certified reference materials 
(CRMs),6 have also been applied for quantitative LA-ICP-MS imaging to overcome the 
drawbacks of matrix matched calibration standards. Although these methods provide 
successful quantification for some samples, in many cases they still do not adequately 
match with the matrix of the original sample. For this reason, developing alternative 
strategies for quantification are required for further improvement. 
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 Inkjet printing is a convenient way to deposit controlled amounts of material in a 
spatially defined way. The homogeneous printout, easy sample preparation and cheap 
instrumentation makes it a potentially promising approach for creating standards for LA-
ICP-MS imaging. Previously, inkjet printing has been used for internal standardization to 
improve signal reproducibility in LA-ICP-MS imaging,11,12 but there are a few reports on 
its use for calibration standards for quantitative imaging.13  
In this chapter, we describe the use of inkjet printing as an alternative approach for 
quantitative LA-ICP-MS imaging of AuNPs in vivo. We have explored whether inkjet-
printed standards can be added as internal standards to tissues of interest in a standard 
addition-type approach. By adding the standards to the tissue that is being imaged, we 
surmised that ‘matrix-matching’ would be ideal.  
3.2. Results and Discussion 
 
Figure 3.1 Structure of the AuNP used in the study 
 
 Positively charged AuNPs with tetraalkylammonium head group (referred to as 
TTMA throughout the chapter) were selected for preparation of inkjet-printed standards. 
The AuNP consists of a 2 nm core and monolayer attached to the core via thiol group 
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(Figure 3.1). The TTMA AuNP solution was prepared by dissolving the NPs in an ink 
formulation, that consisted of 69% water, 20% glycerol, 10% 1,2 hexanediol, 1% 
triethanolamine.14 This formulation was found to be critical for obtaining successful 
printouts from the printer.  
 
Figure 3.2. Illustration of quantification of the printed Au amounts. 
 
Using the CD printing software (Print CD) provided with the printer, different 
printing conditions were investigated in order to find the amounts of Au printed on the 
glass surface. Different black percentages (100, 95, 90, 85, 80, 66, 60, 47, 33, 0 %) were 
selected and printed onto glass surfaces (Figure 3.2). The slides were washed with 10 % 
aqua regia to dissolve the printed gold amounts and soaked for 2 hours prior to the analysis 
with ICP-MS. Quantitative recoveries were obtained from washing the glass slides with 
this method, and the obtained results were plotted in order to generate calibration curves 
for the amounts of Au printed as a function of the % black that was used (Figure 3.3). The 
results indicate that below 60 % black values no amounts of Au are detected. Using % 
black values of 66 % to 100 % allowed a linear calibration curve to be achieved with an 
r2=0.99951 (Figure 3). 
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Figure 3.3. Quantification results of printed amounts of AuNP at different black percentage 
values. 
 Day-to-day variation is one of the major concern for the inkjet-printed standard 
preparation.13 In order to investigate the variability of the printouts from different days, 
calibration curves were generated for selected black percentage values on two different 
days (Figure 3.4). The results indicate that the variation from day-to-day printouts was 
insignificant.  
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Figure 3.4. Day-to-day variation comparison of the printouts obtained from printer 
 
 Following successful quantification of printed Au amounts, the feasibility of inkjet-
printed standards for LA-ICP-MS imaging was investigated. In chapter 2, a quantitative 
LA-ICP-MS imaging method for 2 nm monolayer protected AuNPs using matrix-matched 
standards was developed.15 Optimum instrumental parameters obtained in chapter 2 with 
the matrix-matched standards were also used in this work. Selected black percentages were 
printed as line patterns onto glass slides and a blank control mouse liver tissue sliced was 
placed on top of the printed standards (Figure 3.5).  
 
Figure 3.5. An illustration of the sample preparation procedure for quantitative LA-ICP-
MS imaging with inkjet-printed standards.  
 
Upon placement of the control mouse tissue, the sample was imaged using LA-
ICP-MS. 57Fe signals were used to locate the tissue and generate an image of it as Fe is 
located throughout the tissue. At the same time, 197Au signals were obtained to generate 
images of the inkjet-printed samples. The results obtained from inkjet-printed standards 
were then used to plot calibration curves. Linear calibration curves with r2=0.99296 were 
obtained from the inkjet-printed standards in LA-ICP-MS imaging (Figure 3.6). 
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Figure 3.6. Quantification results obtained from a control mouse tissue placed on top of 
the inkjet-printed standards.  
3.3. Future direction 
 Initial experiments allow us to quantify the printed amounts of the AuNPs from 
different black percentages. Using this information, we can select 6 different black 
percentages to be used for inkjet-printed standards. With the selected inkjet-printed 
standards, a calibration curve can be plotted and linear calibration curves can be achieved 
from these samples with the blank mouse tissue. Overall, these results are promising to 
move forward to use inkjet-printed standards for exact matrix matching with tissues of 
interest. This could be achieved by placing only small part of the tissue on the edge of the 
inkjet-printed standards (Figure 3.7). The inkjet-printed standards and the tissue could be 
imaged simultaneously with the LA-ICP-MS system, and the obtained data could be further 
processed to generate calibration curves.  
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Figure 3.7. An illustration of the usage of the inkjet-printed standards for quantification of 
AuNPs in tissue samples from mice injected with AuNPs. 
 
 Data analysis of the samples could be done by generating histogram bins for each 
of the printed lines. The results could then be extracted to separate the signals coming from 
the tissue samples and the inkjet-printed standards. The obtained averages from the 
histogram bins could be used to generate the calibration curve for the quantification of Au 
amounts in the tissue (Figure 3.8).  
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Figure 3.8. a) Illustration of histogram calculation for generation of calibration curve from 
inkjet-printed standards. b) Calibration curve plotted using the average values of the 
intensity bins obtained from inkjet-printed standards. 
3.4. Conclusion 
 In conclusion, the inkjet-printed standards could possibly be used as an alternative 
strategy for LA-ICP-MS imaging. Quantitative recoveries obtained from the different 
printed AuNP amounts and negligible day-to-day variation suggest that it is a potentially 
promising approach for LA-ICP-MS quantification. Linear calibration curves were also 
obtained from the experiments with blank mouse liver tissue. With the application towards 
AuNP injected mouse tissues, this method might be used for better matrix matching and 
thus better quantitative imaging.   
3.5. Experimental 
3.5.1. Instrumentation 
For all printing experiments, an Epson Artisan 50 inkjet printer was used. It was 
selected over other brands and types due to its piezoelectric print head that does not cause 
any issues with the experimental materials. For example, some brands uses heat-based print 
heads that can affect to the composition of the materials and the quality of the printouts 
obtained.  
3.5.2. Synthesis of AuNP 
 The AuNP used in this study were synthesized using Brust-Schiffrin two-phase 
method.16 Using Murray place exchange reaction, the AuNPs were functionalized with the 
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desired monolayer.17 The details of the synthetic procedure for the synthesis of the 
monolayer can be found in Chapter 2. Following place exchange reaction, AuNPs were 
dialyzed for 72 hours against MilliQ water using Spectra/Por Dialysis Membranes 
(molecular weight cutoff of 1000 Da) to remove excess free ligand.   
3.5.3. Inkjet printing formulation 
 For successful printouts from a piezoelectric print head, the formulation viscosity 
was optimized. As previously noted, we used an organic solvent system that is known to 
enable reliable printouts. The formulation consisted of 69% water, 20% glycerol, 10% 1,2 
hexanediol, and 1% triethanolamine that was then mixed with 1:1 ratio of the AuNPs 
solution. 10 mL of this mixture was then placed into an empty black ink cartridge (obtained 
from Inksupply.com) to be printed.  
3.5.4. Printing of inkjet-printed standards 
 Using the CD printing software, a rectangular shape and a 6 line pattern was created 
for obtaining quantification of AuNPs amount and inkjet-printed standards, respectively. 
Rectangular shapes were drawn using the shape tool in the Print CD software. Using font 
size of 4 and the letter “I” in horizontal orientation, 6 lines of the selected black percentages 
were also printed out. The printed sample were dried overnight and a blank control mouse 
tissue was placed on top of the printed samples prior to their analysis with LA-ICP-MS.  
3.5.5. Quantification of Au amounts printed 
 Using the CD printing software (Print CD) provided with the Epson Artisan 50 
printer, we printed different black percentages (100, 95, 90, 85, 80, 66, 60, 47, 33, 0 %). 
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Glass slides (from Fisher Scientific) were placed onto the CD printing tray and rectangular 
regions of the different black percentages were printed out. Two rectangular regions 
(approximately 3.5x1.7 cm) were printed onto the same glass slide and the slides were cut 
into half. Each half was placed into a different 50 mL centrifuge tube and they were washed 
with 1 mL aqua regia (Aqua regia is highly corrosive and must be handled with extreme 
caution.). After washing the slides with aqua regia, samples were diluted to 10 mL and 
slides were soaked for 2 hours. Following digestion of the samples, the glass slides were 
removed from the solution and the samples were analyzed with ICP-MS. The parameters 
used for ICP-MS analysis were described in Chapter 2. Au standard solution were prepared 
prior to the each experiment (20, 10, 5, 2, 1, 0.5, 0.2, 0 ppb). 
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CHAPTER 4 
 
SURFACE CHARGE CONTROLS THE SUB-ORGAN BIODISTRIBUTION OF 
GOLD NANOPARTICLES  
 
This chapter is adapted from a paper published as: Elci, S. G.; Jiang, Y.; Yan, B.; Kim, S. 
T.; Saha, K.; Moyano, D. F.; Yesilbag Tonga, G.; Jackson, L. C.; Rotello, V. M.; Vachet, 
R. W. ACS Nano 2016, 10, 5536-5542. 
 
4.1. Introduction 
Recent advances in the synthesis and functionalization of nanoparticles (NPs) has 
led to an increasing number of applications in imaging,1,2 drug delivery3,4 and therapeutics.5 
Effective use of nanomaterials as drug delivery vehicles requires them to overcome 
biological barriers, accumulate in specific tissue and sub-tissue regions, and resist rapid 
clearance.6,7  For both active and passive targeted drug delivery applications, it is therefore 
important to understand the effect of NP surface functionality on biological distributions.8 
Several studies have investigated the in vivo biodistributions of differently sized NPs9,10 
but relatively few report the effect of surface functionality of the NPs in vivo.11,12  NP size 
influences how NPs are cleared or stored in the reticulo-endothelial system organs (e.g. 
liver, spleen, etc.) after their uptake by the mononuclear phagocyte system in blood 
stream.13,14 While smaller NPs (< 5 nm) are excreted from the body by renal clearance, 
larger particles (> 100 nm) are filtered by the spleen and sequestered by the liver.15 Particles 
with sizes between these two extremes (5 - 100 nm) typically have longer circulation 
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times.16,17 In this size range the fate of NPs in vivo is likely to be influenced by a range of 
factors, including NP shape and surface chemistry.  
Surface chemistry is a particularly important determinant, influencing cellular 
uptake,18-20 immune system activation,21 and the composition of the protein ‘corona’ that 
develops around NPs in vivo.22,23 To date,  most in vivo applications of nanomaterials have 
involved PEG-functionalized NPs to minimize protein corona formation and concomitant 
rapid NP removal from circulation via opsonization,13,24-26 although binding to plasma 
proteins is still possible, including interactions with IgG and fibrinogen.27 A few studies 
have explored how modification to PEG surface coatings, such as the introduction of 
charged moieties, influences protein corona formation and subsequent interactions with 
components in the blood and uptake by macrophages.12,28-33 Not surprisingly, surface 
chemistry can influence protein adsorption, 31,32 but it also affects uptake by macrophages28-
30,33 and perhaps even plays a more important role than size in NP-cell interactions.12,27,29,33 
Overall, existing work indicates that the influence of NP surface chemistry on the fate of 
the NPs in vivo is complex. Quantitative information about the effect of surface chemistry 
on NP biodistributions will improve our understanding of NP fate in biological systems. 
Moreover, site-specific quantitative information about nanomaterial sub-organ 
distributions, which is, with a few exceptions,34,35 lacking in nanomaterial studies in vivo, 
will yield a deeper understanding of how NP surface chemistry influence biological 
pathways inside organisms.   
In this chapter, we investigate the sub-organ biodistribution of AuNPs with 
different surface charge that have been intravenously injected into mice. We focus on the 
distributions of these AuNPs in the kidney, liver and spleen, as these organs not only tend 
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to accumulate the highest levels of NPs, but they also have distinct cell types that are 
involved in different biological functions, including clearance and immune responses. We 
use laser ablation inductively-coupled plasma imaging (LA-ICP-MS) to quantitatively 
track the sub-organ distributions. Compared to common imaging techniques, such as TEM, 
confocal microscopy, and AFM, the biggest advantage of LA-ICP-MS imaging is the 
ability to provide quantitative information about distributions. Moreover, the technique 
does not require any specific physical property, such as fluorescence, for detection. Our 
studies here show that surface charge influences the sub-organ biodistributions of the 
AuNPs, and the imaging results clearly reveal that surface charge affects the response of 
the immune system to the injected NPs.  
4.2. Results and Discussion 
Functionalized AuNPs with 2 nm cores were injected into mice to explore how 
surface chemistry influences NP sub-organ distribution. Each of the AuNPs has the same 
hydrophobic interior to confer stability, and a tetra(ethyleneglycol) layer to provide 
compatibility and solubility (Figure 4.1). The surface chemistry was varied via the 
headgroup of the attached ligand, giving rise to NPs that differ in charge (Figure 4.1). 
AuNPs 1 and 2 also differ in hydrophobicity. Our previous work showed that the presence 
of serum influences the uptake of these NPs to different extents, making it edifying to study 
their difference in vivo.36 As was observed previously with similar AuNPs,14 differences in 
surface chemistry can have a dramatic effect on the biodistributions of these NPs in the 
mice, as indicated by the total amount of gold accumulated in each organ (Figure 4.2). In 
most cases, the positively-charged AuNPs (AuNPs 1 and 2) accumulate to the greatest 
extent in each organ. Moreover, the liver and spleen accumulate the highest concentrations 
 59 
of the NPs, which is similar to previous observations for cells and tissues.37,38 This 
biodistribution profile likely arises because the reticuloendothelial system plays a dominant 
role in NP clearance.19,39 The liver and spleen are major detoxifying and filtering organs in 
mammals. With a high proportionate blood-flow to these organs together with the 
propensity of positively-charged NPs to been readily taken up into cells,14 it is perhaps not 
surprising that AuNPs 1 and 2 are found most extensively in these organs. 
  
 
Figure 4.1. Design and structure of the AuNPs used in the study 
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Figure 4.2. AuNP concentrations in different organs after 24 hours of injection as 
determined by ICP-MS. The AuNP concentrations were calculated by the gold amount (ng) 
divided by organ weight (g). The error bars correspond to the standard error of the mean 
from measurements of organs from 4 mice.  
Beyond organ-by-organ distributions, we were interested in understanding whether 
surface chemistry influences NP distributions within the different structures of the kidney, 
lung, spleen, and liver. To address this question, we used LA-ICP-MS to quantitatively 
image the NP biodistributions in these organs. Strictly speaking, LA-ICP-MS is an element 
specific technique and thus reports on total gold concentrations, but previous work from 
our groups has shown that AuNPs with the same design remain intact in vivo.40 Moreover, 
the NP surface coating has a noticeable influence on the distribution of these NPs, 
indicating that the technique is probing the locations of the AuNPs. 
The lung and kidney contain relatively low concentrations of AuNPs as compared 
to the liver and spleen, but AuNP distributions in these organs can be readily obtained using 
LA-ICP-MS imaging. The lung tissues are somewhat difficult to image because of the 
fragile nature of this organ. As a result the images do not reveal much beyond the fact that 
all four AuNPs are absent in the alveolar spaces of the lung (Figure 4.3). This observation 
is not surprising given that the alveolar space is a gas-filled region in the lungs.  
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Figure 4.3. Imaging results for the lung tissues. (a) optical and (b) quantitative LA-ICP-
MS images of AuNP 1; c) zoomed-in area illustrating the amount of AuNP 1 in a selected 
area of the lung tissue with various alveolar spaces indicated in black dotted lines; (d) 
optical image after H&E staining of the same region shown in (c), indicating the alveolar 
spaces in black dotted lines.  (e) optical and (f) quantitative LA-ICP-MS images of AuNP 
2; (g) optical and (h) quantitative LA-ICP-MS images of AuNP 3 (i) optical and (j) 
quantitative LA-ICP-MS images of AuNP 4. All scale bars correspond to 0.5 mm. 
 
More provocative is the finding that the AuNPs are distributed in a surface charge-
dependent fashion in the kidney. Images of this organ from mice injected with the 
positively-charged AuNPs 1 and 2 have a more punctate appearance than the images from 
mice injected with AuNPs 3 and 4 (Figure 4.4). Comparing the LA-ICP-MS images with 
H&E stains of the kidney (Figure 4.4c and d) indicate that AuNPs 1 and 2 accumulate in 
the glomeruli (the initial step in filtration in the nephron) of the kidney, whereas AuNP 3 
and 4 do not selectively accumulate in these regions of the kidney. Indeed, AuNP 3 
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accumulates extensively in the arteries that transport blood into the kidney, and AuNP 4 is 
more homogeneously distributed in the organ. Another interesting observation is that 
AuNPs 1, 2, and 4 do not appear to accumulate in the arteries. 
The concentration of the positively-charged AuNPs in the glomeruli of the kidney 
suggests that surface charge influences how these AuNPs are filtered by the kidney. 
Glomeruli are part of the initial stage of filtering by the kidney, playing an important role 
in a process that eventually ends with the excretion of materials from the blood into urine.41 
Glomeruli have pores that are less than 10 nm in diameter, and their membranes are 
negatively-charged, which might explain why the positively-charged AuNPs preferentially 
accumulate in this region of the kidney. Filtering of intact NPs by the kidney is expected 
to be slow because particles larger than 5 nm in hydrodynamic size are not excreted 
efficiently by this organ.42 Quite likely the accumulation of AuNPs 1 and 2 in the glomeruli 
influences the rate at which these particular NPs are excreted relative to AuNPs 3 and 4. 
Future work will investigate this possibility via a more thorough study of the metabolism 
and excretion characteristics of these materials. Clearly, though, surface charge influences 
NP distributions, and LA-ICP-MS images reveal valuable information for better 
understanding biological responses to injected NPs.  
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Figure 4.4. Imaging results for the kidney tissues. (a) optical and (b) quantitative LA-ICP-
MS images of AuNP 1; c) zoomed-in area illustrating the amount of AuNP 1 in a selected 
area of the kidney tissue with an artery vein and glomeruli indicated in yellow and white 
dotted lines, respectively; (d) optical image after H&E staining of the same region shown 
in (c), indicating the artery vein and glomeruli indicated in yellow and white dotted lines. 
(e) optical and (f) quantitative LA-ICP-MS images of AuNP 2; (g) optical image showing 
the artery veins indicated in black arrows and (h) quantitative LA-ICP-MS images of AuNP 
3 and (i) optical and (j) quantitative LA-ICP-MS images of AuNP 4. All scale bars 
correspond to 0.5 mm. 
Upon imaging spleen tissues by LA-ICP-MS, we found that the AuNPs are 
heterogeneously distributed in this organ (Figure 4.5). All four AuNPs accumulate to a 
significant extent in the red pulp region of the spleen, but AuNP 3 (Figure 4.5h) and to a 
lesser extent AuNP 4 (Figure 4.5j) accumulate in the white pulp and the marginal zone 
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between the red and white pulp (Figure 4.5h and Table 4.1). The positively-charged AuNPs 
(i.e. AuNP 1 and AuNP 2) accumulate very little in the white pulp and marginal zone (Table 
1). In fact, in most images, no statistically significant levels of the positively-charged NPs 
are found in the white pulp. 
The observed AuNP distributions provide interesting insight into how surface 
chemistry affects NP fate in vivo, especially in light of the physiological role of the spleen. 
The primary role of the red pulp is to clean the blood of particulate matter, antigens, and 
dead blood cells, whereas the white pulp acts as part of the immune system. The marginal 
zone is the exchange or sieving region between the white and red pulp, and much of the 
immune response generated by the spleen starts in this region.43,44 Consequently, the 
observation that the neutral AuNP 3 is found to the greatest extent in the marginal zone 
and white pulp suggests that this NP may have elicited an immune response to a greater 
extent than the others. It is known that antigen exposure in the marginal zone of the spleen 
can cause the transport of bacteria from the marginal zone to the periarteriolar lymphoid 
sheath of the white pulp.45 It is possible that AuNP 3 is being transported in an analogous 
way, giving rise to its accumulation in this region of the spleen. 
The reasons for the surface chemistry-dependent difference in the AuNP 
distributions are not clear at this point, but it is likely that AuNP 3 is coated with an 
immune-competent protein. Previous work with functionalized NPs having varying PEG 
chain lengths suggested that the protein corona around these NPs was formed by the 
immune-competent proteins IgG and fibrinogen.27 In contrast, the positively-charged 
AuNPs 1 and 2 are almost certainly interacting with negatively charged proteins such as 
serum albumin, which do not elicit an immune response. Perhaps the negatively-charged 
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NPs are coated to a lesser extent with immune-competent proteins, causing them appear to 
a lesser extent in the white pulp than the neutral NP. 
 
Figure 4.5. Imaging results for spleen tissues. (a) optical and (b) quantitative LA-ICP-MS 
images of AuNP 1; c) zoomed-in area illustrating the amount of AuNP 1 around a selected 
white pulp region of the spleen; d) optical image after H&E staining of the same region 
shown in (c), indicating the white pulp region in dark purple, the red pulp region in light 
purple and the marginal zone (region circled by the yellow dashed lines). (e) optical and 
(f) quantitative LA-ICP-MS images of AuNP 2;  (g) optical and (h) quantitative LA-ICP-
MS images of AuNP 3 (i) optical and (j) quantitative LA-ICP-MS images of AuNP 4. All 
scale bars correspond to 0.5 mm.  
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Table 4.1. Percent accumulation of each AuNPs in different regions of the spleen with data 
averaged from three images for each AuNP. 
 Red pulpa* Marginal zoneb* White pulpc* 
AuNP 1 79 ± 8 % 17 ± 5 % 2.1 ± 0.8 % 
AuNP 2 75 ± 3 % 21 ± 2 % 3 ± 1 % 
AuNP 3 60 ± 15 % 30 ± 10 % 10 ± 5 % 
AuNP 4 70 ± 9 % 27 ± 9% 5 ± 2 % 
a The red pulp regions in each image were identified from the H&E stains, optical 
images, and the 57Fe LA-ICP-MS images of the spleen (Figure 4.6).  
b The marginal zone is the ~ 40 µm thick region between the red pulp and white pulp, 
and in the LA-ICP-MS images, this corresponds to a single pixel area surrounding each 
white pulp region.  
c The white pulp regions in each image were identified from the H&E stains, optical 
images, and the 57Fe LA-ICP-MS images of the spleen (Figure 4.6).  
*Average values are calculated based on three images obtained from three separate tissue 
slices (n=3). See experimental section for details about how the gold percentages were 
determined in each case. 
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Figure 4.6. 57Fe images of the spleen tissues. Higher concentrations of Fe are found in the 
red pulp as this region is infused with blood, whereas lower Fe concentrations are found in 
the white pulp. 
 
A comparison of LA-ICP-MS liver images reveals that the positively-charged NPs 
distribute themselves in a more heterogeneous fashion than the neutral or negatively-
charged NPs (Figure 4.7). AuNPs 1 and 2 accumulate in the hepatocytes and endothelial 
regions of the tissue that comprise a large percentage of the liver46 and accumulate very 
little in the Kupffer cells (e.g. Figure 5c and d). In contrast, AuNP 3 (Figure 4.7h) and 
AuNP 4 (Figure 4.7j) distribute more broadly in the liver.  In particular, AuNP 3 seems to 
be equally distributed through the hepatocytes and Kupffer cells. A quantitative basis for 
this conclusion can be found by counting the number of pixels in the LA-ICP-MS images 
that show no detectable gold signal. For AuNP 3, only 7.3% of the pixels are found without 
gold, whereas 26.3%, 44.1%, and 23.5% of the pixels are found without gold for AuNPs 
1, 2, and 4, respectively. 
Another interesting observation is that the positively-charged AuNPs do not appear 
in the blood vessels that transverse the liver. This conclusion is based upon comparisons 
of the Au and 57Fe distributions from the LA-ICP-MS imaging results (e.g. Figure 4.7b and 
4.7f vs. Figure 4.8).  The blood vessels in the Au images for AuNP 1 and 2 have no gold, 
whereas the blood vessels in the images of AuNPs 3 and 4 have significant levels of gold. 
These data are consistent with the low levels of AuNPs 1 and 2 and the relatively high 
levels of AuNP 3 measured in the blood by ICP-MS (Figure 4.2). 
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Just as with the spleen data, the AuNP distributions in the liver suggest that AuNP 
3 is interacting to a greater extent with the immune system than the positively-charged 
AuNPs. This conclusion comes from the homogeneous distribution of AuNP 3, including 
with the Kupffer cells, and the corresponding absence of AuNPs 1 and 2 in these cells 
(Figure 4.7c and d). Kupffer cells have endocytic activity against blood-borne materials 
entering the liver and act as part of the host immune system to clear pathogens and waste 
materials.47 Kupffer cells are effective at removing foreign material from circulation, and 
particular matter and microorganisms are known to adhere to Kupffer cells.48 As speculated 
earlier in the context of the spleen images, it is possible that differential protein corona 
formation around the AuNPs leads to different biodistributions in liver. Another interesting 
conclusion from the liver images is that the positively-charged AuNPs are removed from 
circulation more quickly than neutral and negatively-charged AuNPs as revealed by the 
absence of AuNPs 1 and 2 in the blood vessels 24 h after injection. 
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Figure 4.7. Imaging results for the liver tissues. (a) optical and (b) quantitative LA-ICP-
MS images of AuNP 1; c) zoomed-in area illustrating the amount of AuNP 1 in a selected 
area of the liver tissue with a blood vessel, hepatoctyes and Kupffer cells indicated in 
yellow, white and black dotted lines, respectively; (d) optical image after H&E staining of 
the same region shown in (c), indicating the blood vessel, hepatoctyes and Kupffer cells in 
yellow, white and black dotted lines.  (e) optical and (f) quantitative LA-ICP-MS images 
of AuNP 2; (g) optical and (h) quantitative LA-ICP-MS images of AuNP 3 (i) optical and 
(j) quantitative LA-ICP-MS images of AuNP 4. All scale bars correspond to 0.5 mm. 
 
Figure 4.8. 57Fe images of the liver tissues.  
4.3. Conclusion 
In conclusion, surface charge has a notable effect on NP biodistributions in vivo, 
specifically their sub-organ distributions. LA-ICP-MS images of the kidney show that the 
positively charged AuNPs concentrate in the glomeruli, whereas the neutral and 
negatively-charged AuNPs do not. This observation suggests that the NPs might be 
excreted at different rates that depend on their surface chemistry. Future work will explore 
this finding in greater detail. LA-ICP-MS imaging results also suggest that neutral AuNPs 
are more likely to interact with the immune system, as evidenced by their greater relative 
accumulation in the marginal zone and white pulp regions of the spleen and with the 
 70 
Kupffer cells of the liver. Positively-charged NPs, on the other hand, are found more 
extensively in the filtering regions of the spleen and the detoxifying hepatocytes of the 
liver. In addition, because no measurable gold is found in the liver blood vessels 24 h after 
injection of the positively-charged AuNPs, it is likely that these AuNPs are rapidly cleared 
from circulation, whereas the neutral and negatively-charged NPs circulate longer. The 
negatively-charged AuNPs are cleared more slowly than the positively-charged AuNPs, 
but they do not interact with the immune system as extensively as the neutral AuNPs, as 
suggested by their distributions in the spleen and liver. Overall, LA-ICP-MS imaging gives 
quantitative sub-organ information that can provide a deeper understanding of how NP 
properties affect the biological responses to the injected NPs. Moreover, observations about 
the effect of NP surface functionality on sub-organ biodistribution may provide additional 
valuable information to improve the design of nanotherapeutics for both passive and active 
targeting strategies. For example, some surface coatings may cause NPs to interact with 
the immune system to a greater or lesser extent, and understanding this effect is essential 
for realizing the full implications of a NP-based delivery system.  
4.4. Experimental 
4.4.1. Material 
All the reagents required for the AuNPs syntheses were purchased from Fisher 
Scientific or Sigma-Aldrich, with the exception of chloroauric acid, which was obtained 
from Strem Chemicals Inc. The 8-10 weeks old Balb/C type mice required for the animal 
experiments were obtained from Jackson Laboratory (Bar Harbor, ME). Animals were 
housed in the University of Massachusetts Amherst Animal Care facility. All of the animal 
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experiments were conducted in accordance with the guidelines of the Institutional Animal 
Care and Use Committee (IACUC) at the university. Food and water intake of the mice 
were assessed. Chicken breast and beef liver were purchased from a local market (Big Y). 
The H&E staining kit, nitric acid, hydrochloric acid and hydrogen peroxide were purchased 
from Fisher Scientific. The daily performance solution and Au standard were purchased 
from Perkin Elmer.  
4.4.2. Gold nanoparticle synthesis and characterization 
Using the Brust-Schiffrin two-phase synthesis method, 2 nm core AuNPs were 
synthesized.49 The AuNPs are initially synthesized with pentanethiols as the capping 
monolayer. Once these AuNPs were synthesized, the Murray place exchange method was 
used to functionalize the AuNPs with desired ligand functionality.50,51 Detailed syntheses 
of the ligands that were used in this work can be found in previous work.52 The place 
exchange reaction involved taking 10 mg of the pentanethiol-conjugated AuNPs and 
mixing with 30 mg of the ligand of interest in a mixture of dry dichloromethane (3 mL) 
and methanol (1 mL). This mixture was stirred under nitrogen (N2) for 3 days at 25 °C. 
Then, the precipitate was collected (place-exchanged particles precipitate out) and 
dissolved in distilled water and dialyzed for three days to remove excess ligands, 
pentanethiol, and other salts present in the nanoparticle solution. The products of the 
synthesis, including the ligands and the final nanoparticles, were characterized using NMR 
and mass spectrometry. Figure 1 represents the structure of the AuNPs used in the study. 
For the characterization of AuNPs, the core sizes of the NPs were measured by 
transmission electron microscopy (TEM) on a JEOL100S electron microscope and were 
found to have core diameters of 2.1 ± 0.2 nm (AuNP 1), 2.0 ± 0.1 nm (AuNP 2), 1.8 ± 0.2 
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nm (AuNP 3) and 2.0 ± 0.4 nm (AuNP 4) (Figure 4.9). The AuNPs were also characterized 
by laser-desorption/ionization mass spectrometry (LDI-MS) to confirm the monolayer 
coating.53 Hydrodynamic size and the zeta potential of the particles were measured with 
Malvern NanoZetaSizer (1µM NP concentration in 5 mM phosphate buffer pH=7.4). 
 
Figure 4.9. TEM images of the AuNPs studied in this work and summary of the TEM, 
DLS and zeta potential measurements of the particles. 
4.4.3. Intravenous administration of AuNPs in normal mice 
Solutions of individual AuNPs were prepared at concentrations of 2 μM, and 50 μL 
of each AuNP solution was injected into Balb/c mice via the tail vein. After 24 h, the mice 
were sacrificed via inhalation of carbon dioxide and cervical dislocation. Organs were then 
collected and prepared for analysis. Each organ that was collected was cut into two parts, 
except the kidneys and lungs which are present as a pair in the body. One of the two organs, 
in the case of the kidneys and lungs, or one part of the organs was homogenized and 
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analyzed by ICP-MS for total gold amount. The remaining organ or part of the organ was 
then used for LA-ICP-MS imaging analysis.    
4.4.4. Tissue preparation for imaging  
Liver and spleen tissue samples were sliced to a thickness of 12 μm at -20 °C using 
a LEICA CM1850 cryostat microtome instrument. The sliced tissues were then attached to 
regular glass slides and stored at room temperature until they were analyzed.  
4.4.5. Hematoxylin & Eosin Y (H&E) staining  
Tissue slices were stained using a kit that was obtained from Thermo Fisher 
Scientific. Adjacent slices of the tissues were taken and fixed onto a glass slide. Following 
fixation, the tissues were immersed into distilled water, hematoxylin, bluing reagent, 95% 
ethanol, eosin-y, 100% ethanol and xylene in the order described by the kit’s manual.  
4.4.6. ICP-MS sample preparation and measurements  
Tissue homogenates of the organs were prepared using a 3:1 (v:v) mixture of nitric 
acid (68%) and hydrogen peroxide (30%) to digest each organ overnight. The next day, 0.5 
mL of aqua regia [3:1 (v:v) mixture of nitric acid and hydrochloric acid] was added and 
the sample was then diluted to 10 mL using de-ionized water. (Aqua regia is highly 
corrosive and must be handled with extreme caution.) Gold standard solutions (gold 
concentrations: 20, 10, 5, 2, 1, 0.5, 0.2 and 0 ppb) were prepared prior to each experiment. 
A Perkin Elmer NEXION 300X ICP mass spectrometer (Waltham, MA) was used to 
analyze these samples. Prior to the analysis, daily performance measurements were done 
to ensure the instrument was operating under optimum conditions. The 197Au signals were 
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obtained using the standard operating mode. The ICP-MS conditions can be found in 
Chapter 2.  
4.4.7. LA-ICP-MS measurement conditions and imaging 
A CETAC LSX-213 G2 laser ablation system (Photon Machines, Omaha, NE) that 
was attached to the ICP mass spectrometer via a 2 m length of tubing was used to image 
the tissue samples. Optimization of the laser ablation conditions was first performed using 
pure AuNP samples on glass slides. The optimal conditions can be found in Chapter 2. The 
mass spectrometer was operated using the kinetic energy discrimination mode, which was 
especially important for measurements of 57Fe. 
4.4.8. Data analysis and image generation  
ICP-MS data was analyzed using Excel and Origin 9.0 (from OriginLab, 
Northampton, MA). Images of the analyzed LA-ICP-MS data were generated using the 
software ImageJ. Optical images of the tissues were processed with Adobe Photoshop. 
4.4.9. Matrix-matched standard preparation for ICP-MS 
 This information can be found in experimental section of Chapter 2. 
4.4.10. Gold percentage determination in spleen tissue regions 
The gold concentration in each pixel of the red pulp was determined after 
comparison to a calibration curve as described in the experimental section. The 
concentrations from each pixel were then summed to obtain the total gold concentration in 
the red pulp region, and the percentage was calculated after summing the total gold from 
 75 
each of the three parts of the spleen. We determined the amount in each marginal zone by 
summing the gold concentrations in a single pixel area surrounding each white pulp region. 
The gold concentrations were obtained via comparison to a calibration curve, and the 
reported percentage was calculated in the same manner as with the red pulp. The gold 
concentrations were obtained via comparison to a calibration curve, and the reported 
percentage was calculated in the white pulp in the same manner as with the red pulp and 
marginal zone.  
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CHAPTER 5 
 
NANOPARTICLE STABILITY MONITORING IN TISSUES USING DUAL 
MODE MASS SPECTROMETRIC IMAGING  
5.1. Introduction 
Monolayer-protected nanoparticles (NPs), which are composed of an inorganic 
core and an organic monolayer, are used in a variety of biological applications including 
delivery1,2 and imaging.3,4 For example, functionalized gold NPs (AuNPs) have been 
investigated for siRNA and DNA delivery applications in which the oligonucleotides are 
attached either covalently or via physisorption.5 Similarly, quantum dots (QDs) with 
different surface coatings have been explored for their use in imaging applications in vivo.6 
Effective use of NPs for these applications requires an accurate assessment of monolayer 
stability7 especially in vivo as aggregation and/or degradation of the core, due to monolayer 
instability, can compromise the intended purpose of the NP.8-10 In addition to protecting 
the NP from aggregation and degradation, the monolayer provides additional control over 
NP physical and chemical properties, particularly when interacting with biomolecules.11-14 
The integrity of the monolayer is also crucial because it is known to dictate a particle’s 
fate, including its uptake,15 corona formation,16-18 distribution,19 interactions with the 
biomolecules,20 and clearance. 
Because the application of monolayer-protected NPs depends on the presence of 
the monolayer, the release and/or exchange of these surface molecules must be considered 
to optimally use them in biological settings.21 For example, a robust monolayer is a 
prerequisite for quantum dots (QDs)22,23 to prevent aggregation that deteriorates their 
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fluorescence emission properties. In addition, unstable monolayers lead to direct exposure 
of the core materials to a biological system, which can trigger cell toxicity.24 Semi-stable 
monolayers, however, are desirable for certain applications. For instance, NP monolayers 
can be tailored to respond to stimuli such as biogenic thiols or other biomolecules to release 
cargo for delivery applications, and these stimuli work through destabilization of the 
monolayer.24-26 Hence, monolayer stability control is crucial to fully exploit the potential 
of monolayer-protected NPs in biological applications.  
Characterization of monolayer exchange and release has relied on a variety of 
techniques, including nuclear magnetic resonance (NMR), fluorescence microscopy, 
dynamic light scattering (DLS) and high performance liquid chromatography (HPLC).26-28 
These tools have provided valuable insight into the chemical and structural factors that 
influence NP monolayer stability,29,30 but they are limited to relatively pure samples of 
NPs. Applying these techniques to more complex samples such as cells or tissues is 
considerably more challenging. Gaining insight into the chemical and biochemical factors 
that influence NP stability in vivo is essential for NPs with diagnostic or therapeutic 
potential. Moreover, information about how different tissues influence NP stability is 
important to more deeply understand the biological effects of NPs in vivo.  
Here, using monolayer functionalized AuNPs as a testbed, we describe a dual-mode 
imaging approach that can reveal NP monolayer stability in a site-specific manner. We use 
laser ablation inductively-coupled plasma mass spectrometry (LA-ICP-MS) imaging to 
report on the distributions of Au,31,32 while using laser desorption/ionization (LDI) MS 
imaging to report on the distributions of AuNPs that have intact monolayers.33 A site-
specific comparison of the two images then reveals the extent to which the NPs are still 
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intact. Previously, we demonstrated that ICP-MS and LDI-MS could be used to determine 
the monolayer stability of AuNPs and QDs in cell culture.3,34 The combined imaging 
approach described in the current chapter goes much further, allowing us to reveal how 
different organs and sub-organ cell types influence NP stability in vivo. 
5.2. Results and Discussion 
 
Figure 5.1. Structure of the AuNPs used in this study. 
AuNPs (Figure 5.1) with 2 nm cores that were synthesized and characterized as 
described in experimental section were injected into mice intravenously. After certain time 
points the mice were sacrificed and their organs were collected. To demonstrate the ability 
of the combined imaging approach to report on NP stability, we first investigated the 
stability of selected AuNPs in the liver and spleen. These organs are known to accumulate 
IV-injected NPs to a significant extent due to their role in blood clearance and 
filtration.32,33,35 The liver and spleen differ substantially in their thiol content36,37 and the 
cell types involved in blood clearance, however, meaning that they will influence the 
stability of AuNPs to different extents. The liver has a much higher thiol content than the 
spleen, so one would expect that AuNPs with thiol-linked monolayers would be less stable 
in the liver. To test this idea, we compared the LDI-MS and LA-ICP-MS images of spleen 
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and liver slices from mice injected with AuNP 1 (Figure 5.2). A comparison of these 
images demonstrates that the monolayer stability of AuNP 1 is low in the liver but is 
relatively high in the spleen 24 h after injection. We arrive at this conclusion by comparing 
the signal associated with the monolayer ligand in the LDI-MS images (Figure 5.2b and e) 
with the signal from Au in the LA-ICP-MS images (Figure 5.2c and f). Previously we had 
shown that monolayer ligands are only detected by LDI-MS when they are attached to the 
NP core,34 so the absence of ligand signal in the LDI-MS image of the liver indicates that 
the ligands have been displaced in this organ, presumably by the high concentration of 
thiols. An alternate explanation is that LDI-MS does not work in liver tissue, but this 
possibility is ruled out by control experiments in which AuNPs that are added to liver tissue 
slices give rise to significant ligand ion signal (Figure 5.3). Interestingly, AuNPs with 
dithiol linkers (AuNP 2), which were previously found to be very stable in cell culture, 
including liver cells,34 are also not stable in the liver after 4 h in vivo (Figure 5.4). 
 
Figure 5.2. Comparison of the stability of AuNPs in spleen and liver slices from mice IV-
injected with AuNP 1. Optical images of the spleen (a) and liver (d). LDI-MS images of 
AuNP 1 that report on the monolayer signal for the spleen (b) and liver (e). LA-ICP-MS 
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images that report on the Au signal for the spleen (c), and liver (f). See the experimental 
section and Chapter 2 for instrument parameters and measurement details. 
 
Figure 5.3. LDI mass spectrum of a selected spot in a 12 µm thick liver tissue after pipette 
spotting 1 µL of a 0.5 µM solution of AuNP 1. LH+ = molecular ion signal of the ligand 
attached to AuNP 1 and L-H2S+ = fragment ion signal arising from the loss of H2S from 
the intact ligand. 
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Figure 5.4. LDI-MS and LA-ICP-MS images of liver tissue slices from a mouse injected 
with AuNP 2. 
We next investigated the stability of the particles at different time points (4, 24, and 
48 h) after their injection into the mice. AuNPs 1, 3, and 4 were simultaneously injected, 
and LDI-MS images for each NP’s monolayer signal were generated. We predicted that 
the ligand signal in the LDI-MS images would decrease after longer time points as the 
AuNPs are degraded over time. Similar to other data from the liver, no significant 
monolayer signal is observed during LDI-MS (data not shown) even at the shortest time 
point (i.e. 4 h). This finding suggests that the elevated levels of biogenic thiols in the liver 
rapidly degrade AuNPs in this organ.  The Au distributions from LA-ICP-MS images (e.g. 
Figure 5.5) indicate that the Au amounts first increase and then decrease over time, which 
may indicate some early accumulation of Au despite loss of monolayer stability; however, 
it is difficult to fully conclude this because the data comes from different mice. 
 
Figure 5.5. Time dependent LA-ICP-MS images of the liver tissue slices from three 
separate mice. a), b), and c) are images of Au distributions in the liver slices obtained from 
LA-ICP-MS. d) Bar plots indicating the normalized Au intensity. The normalized intensity 
is calculated by summing the relative pixel intensity for each image (see calculation 
below), dividing this sum by the size of each tissue slice and further normalizing by the 
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total gold amounts in these organs as determined by ICP-MS of partial homogenates. For 
easier comparison of the three time points, the resulting value for the 24 h time point was 
set to 1. 
 
LDI-MS images of the spleen reveal that the monolayer signal for each AuNP 
decreases over time as expected (Figure 5.6a). An evaluation of the ion intensities in these 
images (Figure 5.6b), after normalizing for the size of the tissue, confirms this observation 
and further indicates that the signal drop for each AuNP is similar. In contrast, the Au 
distributions in the spleen, as determined by LA-ICP-MS imaging, indicates that the Au 
amounts remain somewhat constant when the data is properly normalized for mouse-to-
mouse variations (e.g. Figure 5.7 and 5.8). Taken together, the LDI-MS and LA-ICP-MS 
imaging results suggest that greater than 50% of the monolayer stability is lost in the spleen 
over a 48 h time period. 
 
Figure 5.6. a) Time-dependent LDI-MS images of spleen tissue slices for AuNPs 1, 3, and 
4. b) Bar plot of the normalized ion intensities for AuNPs 1, 3, and 4, calculated from 
relative pixel intensities as described in the experimental section. 
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Figure 5.7. An example data set showing the changes in the total Au amount over time in 
the spleen of 3 different mice after IV injection of AuNPs 1, 3 and 4.  
 
 
Figure 5.8. Comparison of time dependent LA-ICP-MS images of the spleen tissues (Error 
bars represent pixel to pixel deviation.) The normalized ion intensity is calculated by 
summing the relative pixel intensity for each image, dividing this sum by the size of each 
tissue slice and further normalizing by the total gold amounts in these organs as determined 
by ICP-MS of partial homogenates. For easier comparison of the three time points, the 
resulting value for the 4 h time point was set to a value of 1. 
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We next examined the effect of monolayer structure on NP stability in vivo. AuNP 
1 and AuNP 5 were compared because we had previously demonstrated in cells that AuNPs 
without the tetraethyleneglycol (TEG) group are less stable.34 NPs with slightly different 
headgroups had to be chosen because the slides used to mount the tissues gave an isobaric 
interference for the monolayers containing a TEG group and a tri-methyl ammonium 
headgroup. LDI-MS and LA-ICP-MS images of the spleen are consistent with our previous 
in vitro work in that the TEG-containing AuNP 1 is found to be more stable than AuNP 5, 
which is missing the TEG group (Figure 5.9). To best compare the two sets of images so 
that this conclusion can be made, we imaged two sets of tissues that had similar total gold 
amounts based on ICP-MS measurements of tissue homogenates (Figure 5.13). In separate 
experiments we found that the relative LDI ionization efficiencies of the two ligands are 
similar (Figure 5.10), allowing for a better comparison of the ion abundances in the LDI-
MS images. Upon comparing the images in Figure 5.9 (left), the LDI-MS signals (shown 
in green) are brighter for AuNP 1, which indicate higher ligand signals, whereas the gold 
signals (shown in yellow) in the LA-ICP-MS images are similar for the two AuNPs. A 
more quantitative comparison can be made by summing the ion abundances in each pixel 
and dividing this value by the total area of the image (Figure 5.9 (right)), while also 
correcting for the slight differences in ionization efficiencies of the two monolayers (Figure 
5.10). From such an analysis, both AuNPs are found to have similar abundances per unit 
area in the LA-ICP-MS images but quite different ion abundances are observed per unit 
area in the LDI-MS images (Figure 5.9 (right)). These comparisons indicate that the 
monolayer of AuNP 5 is less stable than the monolayer of AuNP 1. 
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Figure 5.9. Comparison of the stability of AuNP 1 and AuNP 5 in the spleen. (Left) LDI-
MS and LA-ICP-MS images showing the intact NP and Au distributions, respectively, in 
the spleens of mice IV-injected with either AuNP 1 or AuNP 5. The expanded zoomed-in 
regions illustrate the signal differences observed for AuNP 1 and AuNP 5 in the marginal 
zones of the spleen. (Right) Summed relative ion abundances of the Au and ligand ions 
from the LA-ICP-MS and LDI-MS images in the top part of the figure. The relative pixel 
intensity calculations are described in experimental section. 
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Figure 5.10. Comparison of the LDI-MS ionization efficiencies of AuNP 1 and AuNP 5. 
As described in our previous work,11 cell lysate samples were used to determine the 
ionization efficiencies. A mixture of AuNPs (AuNP 1 = 1 pmol; AuNP 5 = various 
amounts) were spiked into HeLa cell lysate, and the mixture was transferred into a 
centrifuge tube to be centrifuged at 14000 rpm to obtain the pellet.  The obtained pellet 
then was transferred onto the MALDI target. The slope of the graph indicates the ratio of 
the ionization efficiencies, and this value was used to modify the images of the spleen to 
enable an accurate comparison of the results. 
 
More intriguing insight is obtained upon comparing the stability of AuNP 1 and 5 
in different regions of the spleen. The stabilities of the AuNPs are different in two of the 
three regions of the spleen. H&E staining and Fe images from the LA-ICP-MS experiments 
identify these three regions of the spleen (Figure 5.11).  
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Figure 5.11. Example LA-ICP-MS and H&E staining images of a spleen tissue slice from 
a mouse injected with AuNP 5. The Fe image reflects the presence of the blood in the organ 
and can be used to readily distinguish between the red pulp and white pulp regions. The 
red pulp and marginal zone regions of the spleen filter the blood and therefore contain the 
highest concentration of Fe. Less Fe is found in the white pulp because the blood does not 
flow through this region of the spleen. The black regions in the Fe image represent the 
white pulp, and red regions indicate the red pulp. The marginal zone is the interface 
between the red and white pulp regions and extends ~ 40 µm from the white pulp. In the 
H&E stains, the pale pink color indicates the red pulp region, while the dark purple regions 
indicate the white pulp regions. Again, the marginal zone surrounds the white pulp regions 
but also can be seen in the H&E stains as a region with less dense coloring. 
 
To compare NP stability in these different regions, the average ligand and gold 
signals for each spleen region were determined, as described in experimental section. From 
the comparison of the signals from AuNP 1 and AuNP 5, we observe that the ligand signals 
are different in certain spleen regions, while the gold signals are similar. Since ligand loss 
indicates the stability loss, we compared the ligand signals in each of the spleen regions in 
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reference to the gold levels. Analysis of the data in this way indicates that AuNP 1 and 
AuNP 5 have similar stability in the red pulp and white pulp, but AuNP 1 is slightly more 
stable in the marginal zone (Figure 5.12). The reason for the differences in AuNP stability 
in the different regions of the spleen can be somewhat explained by how blood is filtered 
in the spleen. Blood primarily flows through and is filtered in the red pulp, and not 
surprisingly relatively high levels of IV-injected NPs are found here.38,39 In mice, there are 
monocytes in the red pulp that might act to phagocytose and thus destroy some of the 
filtered NPs,40 but evidently both NPs have similar stability in this region. As for the 
marginal zone, only a portion of blood transits this region, where antigen-presenting cells 
are present and the exchange of the blood between the red and white pulp occurs. The 
immune response that can occur in this region might explain why the less stable AuNP 5 
shows greater instability in this region. The similar stability in the white pulp may be due 
to the fact that both AuNPs are somewhat unstable in this region where high concentrations 
of lymphocytes are present that could equally degrade both NPs.   
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Figure 5.12. Overlayed LDI-MS and LA-ICP-MS histograms for the site specific regions 
of AuNP 1 and AuNP 5, indicating the signal intensity distributions of the ligands and Au, 
respectively, for AuNP 1 and AuNP 5. The larger bin numbers represent higher ion 
intensities. The most significant differences between the two AuNPs are found in the 
marginal zone, where the monolayer ligand signals for AuNP 1 have notably higher LDI-
MS signal intensities. 
5.3. Conclusion 
In summary, we have demonstrated that LA-ICP-MS and LDI-MS imaging can be 
used together to monitor NP monolayer stability in vivo. In our approach, LA-ICP-MS 
imaging reports on the distribution of Au in tissues, and LDI-MS images reports on the 
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distributions of AuNPs containing intact monolayers. A comparison of the two images 
from adjacent tissue slices indicates whether or not the AuNPs are intact. The validity of 
this comparison was demonstrated first by observing the expected differences in the 
relative Au and monolayer ligand signals in the spleen and liver and then by observing the 
expected decrease of the ligand signal over time. The utility of obtaining site-specific 
stability information was then demonstrated by comparing the stability of two AuNPs in 
the spleen, where we find that NP stability is most different in the marginal zone of this 
organ, which is consistent with the biological makeup of this region. In future work we 
will develop quantitative imaging protocols that will enable a more quantitative measure 
of the site-specific stability of NPs in vivo. Such methods will provide critical insight into 
how to design NPs of the desired stability, from semi-stable materials used in drug delivery 
to more stable materials that are required in commercial products. 
5.4. Experimental 
5.4.1. Synthesis and characterization of the AuNPs 
Using the Burst-Schiffrin two-phase synthesis method, 2 nm core AuNPs were 
synthesized.41 Briefly, the Brust-Schiffrin two-phase synthesis method was used to 
synthesize pentanethiol-coated AuNPs with core diameters around 2 nm by reducing the 
Au salt. Once these AuNPs were synthesized, the Murray place exchange method was used 
to functionalize the AuNPs with the desired functionality.42,43 Previously synthesized 
ligands were mixed in excess with the pentanethiol-coated AuNPs and allowed to place-
exchange. After the place exchange reaction, the sample was filtered and dialyzed for three 
days to remove the excess ligand/pentanethiol mix.  
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The structures of the AuNPs used in the study can be found in Figure 5.1. The 
AuNP sizes were determined by transmission electron microscopy (TEM) and dynamic 
light scattering (DLS), and their surface charges were obtained from zeta potential 
measurements as previously described.33,34 Table 5.1 shows the TEM, DLS and zeta 
potential measurements of all the AuNPs studied in this work. All AuNPs were also 
characterized by laser-desorption/ionization mass spectrometry (LDI-MS) to confirm the 
identity of the monolayer coating.44  
 
Table 5.1. Summary of the TEM, DLS, and zeta potential results for the studied AuNPs. 
 TEM (nm) DLS (nm) Zeta potential 
AuNP 1 2.0 ± 0.1 14 ± 4 + 21± 6 
AuNP 2  2.2 ± 0.3 8 ± 2 + 26 ± 9 
AuNP 3 1.9 ± 0.2 11 ± 2 + 24 ± 9 
AuNP 4 1.9 ± 0.2 13 ± 2 + 22 ± 8 
AuNP 5 2.2 ± 0.3 8 ± 1 + 24 ± 4 
 
5.4.2. Animal experiments 
Solutions of individual AuNPs were prepared at concentrations of 2 μM, and 50 μL 
of each AuNP solution was injected into Balb/c mice via the tail vein. After certain time 
points, the mice were sacrificed via inhalation of carbon dioxide and cervical dislocation. 
Organs were then collected and prepared for analysis. Each organ that was collected was 
flash-frozen using liquid N2. These frozen tissues were then sliced to 12 µm using a LEICA 
CM1850 cyrostat and placed on either an ITO glass slide (for AuNP 1-4 containing 
samples) or a metal slide (for AuNP 1 and AuNP 5 for the spleen comparison) for LDI-MS 
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imaging. Adjacent slices were placed on a regular glass slide for LA-ICP-MS imaging and 
H&E staining.   
5.4.3. H&E staining 
Tissue slices were stained using a kit that was obtained from ThermoFisher 
Scientific. Adjacent slices of the tissues were used by immersing the tissues into distilled 
water, hematoxylin, bluing reagent, 95% ethanol, eosin-y, 100% ethanol and xylene in the 
order described by the kit’s manual.  
5.4.4. LDI-MS instrument parameters 
LDI-MS imaging was done using a Bruker Autoflex III MALDI-TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany), which is equipped with a Smartbeam 
2 Nd:YAG laser. LDI-MS images were constructed using the FlexImaging 2.1 software 
package. LDI-MS operating conditions were as follows: ion source 1 = 19.00 kV, ion 
source 2 = 16.60 kV, lens voltage = 8.44 kV, reflector voltage = 20.00 kV, reflector voltage 
2 = 9.69 kV, and positive reflectron mode with a mass range of 100−1200 Da. A total of 
50 laser shots were measured per position. In almost all cases, the step width between laser 
shots was 25 μm. The laser energy was optimized to ~ 61 μJ/pulse. 
5.4.5. LA-ICP-MS instrumental parameters 
A Perkin Elmer Nexion 300 X ICP-MS (Perkin Elmer, Shelton, CT, USA) and a 
CETAC LSX-213 G2 laser ablation system (Photon Machines, Omaha, NE, USA) were 
used for the LA-ICP-MS imaging experiments. The optimum parameters for the imaging 
are given in Chapter 2. 
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5.4.6. Relative pixel intensity calculation 
Using ImageJ for each tissue image, a histogram of the pixel intensity distribution 
was obtained in the RGB mode (RGB corresponds to the red green blue color channels 
present in a given image). These histogram values were then copied to Excel into 
corresponding two columns; one with the RGB value and the second one with the intensity 
count. The relative pixel intensities were then calculated by multiplying the RGB value 
with the pixel count and divided by the total number of pixel count. Using ImageJ, the 
areas of the tissues were obtained and used to calculate the relative pixel intensity per area. 
The relative pixel intensity calculation is given below. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑝𝑖𝑥𝑒𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 =  
Σ(𝑝𝑖𝑥𝑒𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)𝑥 (𝑝𝑖𝑥𝑒𝑙 𝑛𝑢𝑚𝑏𝑒𝑟)
Σ 𝑝𝑖𝑥𝑒𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
 
5.4.7. ICP-MS sample preparation and measurements 
The organs were dissolved using a 3:1 (v:v) mixture of nitric acid (68%) and 
hydrogen peroxide (30%) to digest each organ overnight. The next day, 0.5 mL of aqua 
regia [3:1 (v:v) mixture of nitric acid and hydrochloric acid] was added and the sample was 
then diluted to 10 mL using de-ionized water. (Aqua regia is highly corrosive and must 
be handled with extreme caution.) Gold standard solutions (gold concentrations: 20, 10, 
5, 2, 1, 0.5, 0.2 and 0 ppb) were prepared prior to each experiment. A Perkin Elmer 
NEXION 300X ICP mass spectrometer (Waltham, MA) was used to analyze the samples. 
Prior to the analysis, daily performance measurements were done to ensure the instrument 
was operating under optimum conditions. The 197Au signals were obtained using the 
standard operating mode.  
 
 98 
 
Figure 5.13. Total gold amounts in ng/g in mouse tissue homogenates from ICP-MS 
measurements. Mice were IV injected with 50 µL of a 2 µM solution of the indicated 
AuNP. (n = 3 for AuNP 1, but n = 1 for AuNP 5 because of two unsuccessful injections of 
the NPs into the three mice). 
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CHAPTER 6 
 
SUMMARY AND FUTURE WORK 
6.1 Dissertation Summary 
 In this dissertation, the mass spectrometric imaging of AuNPs investigated to reveal 
their sub-organ biodistribution and stability in vivo. Using elemental imaging technique 
ICP-MS and its hyphenation with a laser ablation system provided sub-organ 
biodistribution information about AuNPs. Using this method, the quantities of AuNPs in 
sub-organ regions were also assessed. In addition, the dual mode imaging of AuNPs 
provided by LA-ICP-MS and LDI-MS allowed us to monitor the stability of the AuNPs in 
a site-specific manner.  
 First, using LA-ICP-MS imaging, quantitative images of the AuNPs were obtained. 
The matrix-matched quantification approach was investigated to select an appropriate 
matrix that could be used to quantify AuNPs in tissue. Chicken breast and beef liver were 
found to be appropriate for obtaining accurate quantification. During these analyses, 
differences were observed in the biodistribution of AuNPs with varying surface 
functionalities and these findings were further investigated. Our approach provides useful 
insight into not only how NPs distribute but also how they are processed in vivo. In 
addition, proper matrix selection is essential for accurate quantification of AuNPs in 
tissues.  
 Second, inkjet printing as an alternative quantification approach was studied for 
LA-ICP-MS imaging. Initial findings show no variation in the day-to-day printing and 
demonstrate that linear calibration curves can be obtained. Printing of the standard pattern 
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and imaging with a AuNP free mouse tissue also showed linearity in calibration curve. 
Application towards its use with AuNP injected mouse tissues will be investigated in the 
future. In addition to be an alternative quantification strategy for the LA-ICP-MS imaging, 
this method will also provide a standard addition like approach, which will be adding 
standards to the tissue that is being imaged. By doing so, the “matrix matching” will be 
ideal.  
 Third, the initial observation of the differences in the biodistribution of AuNPs in 
mouse tissues was further investigated. Different AuNP surface functionalities lead to 
differences in the biodistribution of the AuNPs. With the help of H&E staining, the sub-
organ regions were located, and the amounts of AuNPs in these sub-organ levels were 
determined using the quantitative images obtained.  
 Finally, a dual mode imaging approach that combined both elemental and 
molecular imaging was used to investigate the stability of AuNPs. Organ biocomposition, 
time of exposure, and NP surface chemistry, were examined to determine the stability of 
the particles in vivo. A comparison of the stability in liver and spleen revealed that different 
biochemical compositios of the organ can substantially affect the stability of NPs in vivo. 
NPs slowly lose their stability over time within the same organ, indicating degradation of 
AuNPs. Different surface monolayer attached to the AuNPs also caused changes in their 
stability within same organ biocomposition. 
 Overall, the findings obtained in this dissertation should improve our understanding 
of the in vivo fate of AuNPs. It also opens up new areas of research that could help us 
design better monolayers for AuNPs used in drug delivery applications. Possible areas of 
future work are described in the next section. 
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6.2 Future directions 
 In the following sections, potential new applications and improvements for mass 
spectrometric imaging of AuNPs will be described to understand more about the interaction 
of AuNPs with biosystems. 
6.2.1 Quantitative dual mode imaging for stability of AuNPs in vivo 
 Qualitative results demonstrate that the stability of NPs are affected by three 
parameters. Although it was concluded that NP stability differed under these parameters, 
it is important to quantify the stability of the NPs. Chapters 2 and 3 demonstrated the 
quantitative ability and methods that can be applied for LA-ICP-MS imaging. These same 
strategies could also be applied for obtaining quantitative images of the AuNPs in LDI-MS 
imaging. Matrix-matched quantification standards or inkjet-printed standards could be 
prepared, and they could be used for quantification of both the surface monolayer and the 
core of the AuNPs. One of the biggest challenge for the applicability of these methods is 
to accurately obtain the monolayer amount that is present in the standard samples. That can 
be done by digesting the AuNPs with KI/I2 solution and then analyzing the resulting 
solution by HPLC to find the quantity of the monolayer present on the AuNPs. 
6.2.2 Dual mode imaging to track nanocapsules in vivo 
 For the delivery of the drug molecules, nanocapsules can be used to effectively 
encapsulate the therapeutic cargo.1-3 Nanocapsules encapsulate the drug molecules, which 
can then carry the cargo to the desired location in the biosystem. Among various types of 
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nanocapsules, nanoparticle-stabilized nanocapsules (NPSCs) provide better stability 
compared their microcapsule counterparts and the oil-in-water emulsion created is ideal 
for delivery of hydrophobic drugs.3 Dual mode imaging could be used to both track the 
delivery of the drug molecules and to understand the effects of the remaining nanoparticles 
in vivo. Elemental imaging of the AuNP core using LA-ICP-MS would provide the location 
of the AuNPs, while, the molecular imaging using LDI-MS would reveal the location of 
the drug molecules and it would allow us to track and obtain information pertaining to the 
success of the delivery.  
6.2.3 Modulation of the design of the NPs for immune response 
 Investigating the sub-organ biodistribution of AuNPs demonstrated that the NPs 
surface charge dictates the biodistribution. One of the findings showed us that AuNPs with 
a neutral charge accumulate more in the immunogenic parts of the tissues. This information 
can be used to modulate AuNPs surfaces to control the immune response generated.4 These 
newly designed AuNPs could then be used in therapeutic applications. Previously, 
hydrophobic surface functionalities were investigated for their immune response capability 
and findings demonstrated that a linear relationship between the immune response 
generated and the hydrophobicity of the AuNPs exists.5 Although these results are 
promising, one of the concerns with the hydrophobic AuNPs are their cytotoxicity. Since 
our results demonstrated that the neutral surface functionalities can also trigger the immune 
response, design of new particles that having both of these monolayers to modulate the 
immune response generated could overcome this problem. For initial design, mixed 
monolayer AuNPs with neutral and hydrophobic ligands could be synthesized readily and 
used as a testbed.  
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6.2.4. 3D imaging of whole tissue using LA-ICP-MS 
 A 3D imaging approach would be beneficial since the 2D representation of the 
tissues are limited to a certain section of the tissue and the tissue inhomogeneity may result 
in an uncharacteristic representation of small scale features within individual 2D sections. 
In addition, 3D imaging could reveal isolated hotspots in larger volumes within the organ 
that might not be seen in a single cross-section. Consecutive sections of the tissue samples 
can be obtained by carefully slicing the tissue samples and images of the tissues can be 
generated using LA-ICP-MS. With a house built software (e.g MATLAB script), the 
images obtained from LA-ICP-MS analysis would compiled to form the 3D image of the 
whole tissue. Developments in the LA system and ICP-MS instrumentation would also 
help reduce the time required for the analysis of the samples.  
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APPENDIX  
CHANGES MAY OCCUR IN LIVER BIOCOMPOSITION AFTER THE LOSS 
OF AUNPS STABILITY 
 
AuNP stability in the liver is low even only 4 hours after injection. It is known that liver 
has a high concentration of biogenic thiols, such as glutathione (GSH), cysteine (Cys) and 
homocycteine (Hcys).1,2 The main role of these biomolecules are to detoxify the liver and 
remove the reactive oxygen species (ROS). GSH is one of the most common and abundant 
biogenic thiol in the liver and it takes places in oxidative detoxification, especially the 
removal of the peroxidation products.3,4 Biogenic thiols, such as GSH, are likely to 
compete with the monolayers for binding to the surface of the Au core.5 The stability loss 
of the AuNPs in liver indicates that the biogenic thiols successfully displace the 
monolayers. As a result of these stability loss, it is possible that the concentration of active 
biogenic thiols is decreased due to the presence of the AuNPs. To confirm this hypothesis 
further analysis would be required. If the biogenic thiols in liver do decrease in 
concentration, then less thiols would be available for scavenging ROS,6 an associated 
increase in ROS levels could lead to the cell and organ dysfunction. The extent to which 
this occurs, however, would depend upon the levels of biogenic thiols that are recruited to 
destabilize the AuNPs. One might also predict that oxidative damage to the liver would 
increase, and this occurrence could be confirmed by measuring the extent of protein 
oxidation in this tissue.  
References 
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